# EDGAR Filing Document

**Accession Number:** 0001915302
**File Stem:** 0001669191-23-000006
**Filing Date:** 2023-1
**Character Count:** 138213
**Document Hash:** 4d00811cb435078a22cfd1ec4ebd1434
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001669191-23-000006.hdr.sgml**: 20230104

**ACCESSION NUMBER**: 0001669191-23-000006

**CONFORMED SUBMISSION TYPE**: C/A

**PUBLIC DOCUMENT COUNT**: 8

**FILED AS OF DATE**: 20230104

**DATE AS OF CHANGE**: 20230104

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Addiction Cure Therapeutic Sciences Inc
- **CENTRAL INDEX KEY:** 0001915302
- **IRS NUMBER:** 863298719
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** C/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 020-30892
- **FILM NUMBER:** 23507100

**BUSINESS ADDRESS:**
- **STREET 1:** 6574 NORTH STATE RD 7 #277
- **CITY:** COCONUT CREEK
- **STATE:** FL
- **ZIP:** 33073
- **BUSINESS PHONE:** 954-732-9122

**MAIL ADDRESS:**
- **STREET 1:** 6574 NORTH STATE ROAD 7
- **STREET 2:** SUITE 277
- **CITY:** COCONUT CREEK
- **STATE:** FL
- **ZIP:** 34786

## Ex-99

html![](offeringpage.jpg)

### Attached PDF Documents

**Attachment 1:** `offeringstatement.pdf`

# Offering Statement for Addiction Cure Therapeutic Sciences Inc

This document is generated by a website that is operated by Netcapital Systems LLC ('Netcapital'), which is not a registered broker-dealer. Netcapital does not give investment advice, endorsement, analysis or recommendations with respect to any securities. All securities listed here are being offered by, and all information included in this document are the responsibility of, the applicable issuer of such securities. Netcapital has not taken any steps to verify the adequacy, accuracy or completeness of any information. Neither Netcapital nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy or completeness of any information in this document or the use of information in this document.

All Regulation CF offerings are conducted through Netcapital Funding Portal Inc. ('Portal'), an affiliate of Netcapital, and a FINRA/SEC registered funding-portal. For inquiries related to Regulation CF securities activity, contact Netcapital Funding Portal Inc.:

**Paul Riss:**

paul@netcapital.com

Netcapital and Portal do not make investment recommendations and no communication, through this website or in any other medium, should be construed as a recommendation for any security offered on or off this investment platform. Equity crowdfunding investments in private placements, Regulation A, D and CF offerings, and start-up investments in particular are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investments through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Additionally, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns. In the most sensible investment strategy for start-up investing, start-ups should only be part of your overall investment portfolio. Further, the start-up portion of your portfolio may include a balanced portfolio of different start-ups. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.

The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company's control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

## The Company

### 1. What is the name of the issuer?

Addiction Cure Therapeutic Sciences Inc

6574 North State Road 7

Suite 277

Coconut Creek, FL 34786

## Eligibility

2. The following are true for Addiction Cure Therapeutic Sciences Inc:

- Organized under, and subject to, the laws of a State or territory of the United States or the District of Columbia.
- Not subject to the requirement to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934.
- Not an investment company registered or required to be registered under the Investment Company Act of 1940.
- Not ineligible to rely on this exemption under Section 4(a)(6) of the Securities Act as a result of a disqualification specified in Rule 503(a) of Regulation Crowdfunding. (For more information about these disqualifications, see Question 30 of this Question and Answer format).
- Has filed with the Commission and provided to investors, to the extent required, the ongoing annual reports required by Regulation Crowdfunding during the two years immediately preceding the filing of this offering statement (or for such shorter period that the issuer was required to file such reports).
- Not a development stage company that (a) has no specific business plan or (b) has indicated that its business plan is to engage in a merger or acquisition with an unidentified company or companies.

3. Has the issuer or any of its predecessors previously failed to comply with the ongoing reporting requirements of Rule 202 of Regulation Crowdfunding?

No.

## Directors, Officers and Promoters of the Company

4. The following individuals (or entities) represent the company as a director, officer or promoter of the offering:

Name

Michael Lambert

Principal occupation and employment responsibilities during at least the last three (3) years with start and ending dates

| Start Date | End Date | Company | Position / Title |
| --- | --- | --- | --- |
| 01/01/2022 | Present | Mike Lambert Consulting | Owner/Manager |
| 10/01/2013 | Present | Ternary Triangle | Owner/Operator |
| 04/28/2020 | Present | Addiction Cure Therapeutic Sciences Inc COO |  |

Short Bio: Over the past 30 years Mike has been building and managing businesses and media properties; maintaining a passionate creative culture while producing growth and revenue. A creative team leader,

Mike has utilized his vast network to manage multi-million dollar projects with fortune 500 Companies and National Brands throughout the US & Canada. Having started numerous Companies, Mike possesses P&L Experience and knows how to drive revenue, sales, & marketing objectives. His founded a TV Production Company and Media Company. He has participated in two IPO's, securing funding and investors. Mike is a creative force with a keen business sense. He started his career in the cable TV industry and by 1990 was by writing, producing, directing, and then syndicating the weekly TV Series KIDSPORTS TV. He has also successfully produced a weekly women's health TV Series for Lifetime TV - TODAY'S HEALTH, a daily show for WE - Women's Entertainment, and produced a 1⁄2 hour National TV Special featuring Joan Rivers. He is an expert at finding new markets and unique verticals, and reorganizing existing assets to extract more revenue. In 2003, he drove the expansion of RMS Networks' Retail TV Networks into Canada and in 2005 assisted in building a $1 million annual recurring revenue stream with Comcast out of the Companies' existing assets. In 2009 Mike founded and operated Planet Impact and in 2014 founded Ternary Triangle Ad Agency and Business Consulting Mike is from St. Charles IL, and graduated from University of Maryland, College Park, with his Bachelor of Science in Economics and received his MBA in Marketing from Florida Atlantic University. He was a four-time All American Student Athlete, member of the US National Swim Team (1987-1989), and received numerous University of Maryland and Conference / ACC Awards for academic achievement, athletic ability, and leadership. Mike currently serves as CMO of a Private Equity Investment Group. Work Experience: https://www.linkedin.com/in/mike-lambert-187b07a4/

**Name**

Rick Garcia

***Principal occupation and employment responsibilities during at least the last three (3) years with start and ending dates***

| Start Date | End Date | Company | Position / Title |
| --- | --- | --- | --- |
| 11/02/2017 | Present | Zimmerman Advertising | Vice President |
| 04/28/2020 | Present | Addiction Cure Therapeutic Sciences Inc | CMO |

Short Bio: At seventeen, Rick began working at Martin Recording in El Paso, TX. By nineteen he moved to Florida and started working for National Cine Equipment of Florida, where Rick learned the fundamentals of shooting, lighting and editing on film. He quickly moved into sales and marketing. At twenty-one, Rick opened his first business, Indigo Films, providing high quality production and post-production services to South American clients. At twenty-two, Rick traveled throughout the Yucatan Peninsula and Central America filming various documentaries about the Mayan culture. Upon his return to South Florida in 1995, Rick expanded into sales and film transfer and began working for Post Edge, Inc, then Manhattan Transfer, as their South American Sales Account Executive. His role grew into Director of Film Transfer, as Rick developed a new South American sales strategy and steadily increased sales. This allowed him to become well established in the film industry and grow his list of achievements. In 2000, Rick opened The Post Office, Inc. After many successful years, in 2005, Rick joined forces with SunDog Films, out of Toronto, Canada, and opened SunDog South. His work as a producer won him several awards with Subway, Burger King, and others, as well as an Emmy Award. In 2009, SunDog South became Red Design and Post, LLC, (RED). Rick co-owned and operated RED for 7 years. Currently, Rick is Vice President of Zimmerman Advertising where he has been since 2017 and now manages one of the largest post-production studios in the Southeast, which produces approximately 30,000 commercials every year. Rick is a husband and father and is heavily involved in the community. He serves on the board of Eco Life Concepts, a not-for-profit organization creating green awareness. Work Experience: https://www.linkedin.com/in/rick-garcia-55679459/

**Name**

Jack Levine

***Principal occupation and employment responsibilities during at least the last three (3) years with start and ending dates***

| Start Date | End Date | Company | Position / Title |
| --- | --- | --- | --- |
| 04/28/2020 | Present | Addiction Cure Therapeutic Sciences Inc | CEO/President |
| 12/06/2009 | 12/31/2021 | Hamilton Energy Resource Opportunities LLC | Founder/Manager |
| 08/17/2009 | Present | Great Hope Publishing LLC | Founder/Manager |
| 01/01/1993 | Present | Voice of God Ministry Inc. | Founder/Director |
| 01/01/1999 | Present | Dimension Funding Corp | CEO |
| 01/01/2003 | Present | Jack Alan Levine Consulting | CEO |
| 12/01/2015 | Present | Purpose Church Orlando | Executive Pastor |
| 08/01/2012 | Present | Life Solution Seminars LLC | Executive Director |

Short Bio: Jack worked for some of the top advertising agencies on Madison Avenue including NW Ayer and Bozell & Jacobs, on some of the largest accounts in the country (AT&T, US Army and Dupont). Jack was also the founder of ADCLUB and was featured in ADWEEK and AD AGE Magazines and in advertising legends Whit Hobbs book 'What I love About Advertising'. He started his own Ad Agency in 1985, then founded and managed a successful television production company in South Florida. For over a decade he served as Executive Producer on tens of national television shows and thousands of commercials. He sold that business in 2002 to devote more time and effort to entrepreneurial activities and philanthropy. Jack continues to use his business skills and entrepreneurial gifts to own and build companies in Solar Energy, Media, Specialty Food Distribution, Publishing, Real Estate and Advertising/Marketing/Sales consulting. Jack remains a sought after Business advisor to many companies, executives and business owners. He is an accomplished author with eleven books to his credit including Addiction and Recovery Handbook, My Addict Your Addict, The Motivated Life and Success Blast and Don't Blow It With God. Jack also developed a breakthrough online video program for people struggling with addiction and their families to help them understand and overcome addiction called Free For Life At Last. Since 1998 Jack has been speaking as a guest speaker to tens of thousands of people at a variety of men's conferences, companies, colleges, churches and organizations. His favorite topics are about overcoming addiction, business and faith. He also served for years on the Board of Directors at Oasis Compassion Agency and Changed Lives Church. A licensed minister since 2006, he served as Director of Men's Ministry for 12 years at Boca Glades Church in Boca Raton. Currently, Jack serves as Executive Pastor at Purpose Church Orlando in Winter Garden. Jack graduated with a dual degree from The Newhouse school of Public Communications at Syracuse University in Advertising and Sociology. Work Experience:

## Principal Security Holders

5. Provide the name and ownership level of each person, as of the most recent practicable date, who is the beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, calculated on the basis of voting power. To calculate total voting power, include all securities for which the person directly or indirectly has or shares the voting power, which includes the power to vote or to direct the voting of such securities. If the person has the right to acquire voting power of such securities within 60 days, including through the exercise of any option, warrant or right, the conversion of a security, or other arrangement, or if securities are held by a member of the family, through corporations or partnerships, or otherwise in a manner that would allow a person to direct or control the voting of the securities (or share in such direction or control - as, for example, a co-trustee) they should be included as being 'beneficially owned.' You should include an explanation of these circumstances in a footnote to the 'Number of and Class of Securities Now Held.' To calculate outstanding voting equity securities, assume all outstanding options are exercised and all outstanding convertible securities converted.

### **Jack Levine (Through Elson Holdings LLC)**

| Securities: | 10,200,000 |
| --- | --- |
| Class: | Common Stock |
| Voting Power: | 78.6% |

### **Jack Levine (Through Elson Holdings LLC)**

| Securities: | 2,000 |
| --- | --- |
| Class: | Preferred Stock |
| Voting Power: | 78.6% |

### **Rick Garcia (Through YLINE LLC)**

| Securities: | 5,300,000 |
| --- | --- |
| Class: | Common Stock |
| Voting Power: | 20.6% |

## **Business and Anticipated Business Plan**

### **6. Describe in detail the business of the issuer and the anticipated business plan of the issuer.**

Quick description: Addiction Cure Therapeutic Sciences Inc. is a biotech firm advancing therapeutics aimed at treating and curing the devastating disease of drug and alcohol addiction. The Company plans to develop products designed to provide a functional cure for addiction, and long-term benefits for those struggling with addiction. Our mission: To by any means possible find a chemical cure for drug and alcohol addiction; to bring an end to the miserable suffering, life destroying, dream crushing, family ruining scourge of drug and alcohol addiction. Pursue multiple scientific concepts and theories to discover life-changing treatments and cures that transform the lives of people struggling with drug and alcohol addiction. Addiction Cure Therapeutic Sciences Inc. has already begun the process of testing the first of two epigenetic molecules our scientists have deemed potential candidates to find a cure. That testing is occurring at LSU Shreveport's LARC - Louisiana Addiction Research Center. Additional testing of the first of two endocannabinoid compounds that our scientists have also identified as candidates that can lead to a cure are scheduled to begin. The current team of scientists and scientific advisory board are made up of well-known research scientists in the cancer, addiction recovery and research fields. We aim for our tests to produce a cure that we can bring to market to the population struggling with addiction. It is possible that during research, testing and development searching for a cure we would develop and market other products that are able to assist and help those struggling with addiction. Down the road, to facilitate growth management, we could consider potential revenue sources related to addiction in areas such as telemedicine, nutraceuticals, detox etc.

## Risk Factors

*A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment.*

*In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document.*

*The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature.*

*These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.*

### **7. Material factors that make an investment in Addiction Cure Therapeutic Sciences Inc speculative or risky:**

1. We face risks related to health epidemics and other outbreaks, which could significantly disrupt the Company's operations and could have a material adverse impact on us. The outbreak of pandemics and epidemics could materially and adversely affect the Company's business, financial condition, and results of operations. If a pandemic occurs in areas in which we have material operations or sales, the Company's business activities originating from affected areas, including sales, materials, and supply chain related activities, could be adversely affected. Disruptive activities could include the temporary closure of facilities used in the Company's supply chain processes, restrictions on the export or shipment of products necessary to run the Company's business, business closures in impacted areas, and restrictions on the Company's employees' or consultants' ability to travel and to meet with customers, vendors or other business relationships. The extent to which a pandemic or other health outbreak impacts the Company's results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of a virus and the actions to contain it or treat its impact, among others. Pandemics can also result in social, economic, and labor instability which may adversely impact the Company's business. If the Company's employees or employees of any of the Company's vendors, suppliers or customers become ill or are quarantined and in either or both events are therefore unable to work, the Company's operations could be subject to disruption. The extent to which a pandemic affects the Company's results will depend on future developments that are highly uncertain and cannot be predicted.
2. The Company may extend the Offering deadline beyond what is currently stated herein. This means that your investment may continue to be held in escrow while the Company attempts to raise the maximum offering amount even after the Offering deadline stated herein is reached. Your investment will not be accruing interest during this time and will simply be held until such time that Offering is closed, at which time it will be released to the Company to be used as set forth herein. Upon or shortly after release of such funds to the Company, the Securities will be issued and distributed to you.
3. No governmental agency has reviewed the Company's offering and no state or federal agency has passed upon either the adequacy of the disclosure contained herein or the fairness of the terms of this offering. The exemptions relied upon for this offering are significantly dependent upon the accuracy of the representations of the investors to be made to the Company in connection with this offering. In the event that any such representations prove to be untrue, the registration exemptions relied upon by the Company in selling the securities might not be available and substantial liability to the Company would result under applicable securities laws for rescission or damages.

1. 4. The Company does not anticipate paying any cash dividends for the foreseeable future. The Company currently intends to retain future earnings, if any, for the foreseeable future, to repay indebtedness and to support its business. The Company does not intend in the foreseeable future to pay any dividends to holders of its shares of common stock.
2. 5. The failure to attract and retain key employees could hurt our business, and our management does not have extensive experience in the operation of businesses such as ours. Our success also depends upon our ability to attract and retain numerous highly qualified employees. Our failure to attract and retain skilled management and employees may prevent or delay us from pursuing certain opportunities. If we fail to successfully fill many management roles, fail to fully integrate new members of our management team, lose the services of key personnel, or fail to attract additional qualified personnel, it will be significantly more difficult for us to achieve our growth strategies and success.
3. 6. We are highly dependent on the services of our founder. Our future business and results of operations depend in significant part upon the continued contributions of our CEO and founder. If we lose those services or if they fail to perform in their current position, or if we are not able to attract and retain skilled employees in addition to our CEO and the current team, this could adversely affect the development of our business plan and harm our business. In addition, the loss of any other member of the board of directors or executive officers could harm the Company's business, financial condition, cash flow and results of operations.
4. 7. Our management may not be able to control costs in an effective or timely manner. The Company's management anticipates it can use reasonable efforts to assess, predict and control costs and expenses. However, implementing our business plan may require more employees, capital equipment, supplies or other expenditure items than management has predicted. Likewise, the cost of compensating employees and consultants or other operating costs may be higher than management's estimates, which could lead to sustained losses.
5. 8. Start-up investing is risky. Investing in early-stage companies is very risky, highly speculative, and should not be made by anyone who cannot afford to lose their entire investment. Unlike an investment in a mature business where there is a track record of revenue and income, the success of a startup or early-stage venture often relies on the development of a new product or service that may or may not find a market. Before investing, you should carefully consider the specific risks and disclosures related to both this offering type and the Company.
6. 9. Your shares are not easily transferable. You should not plan on being able to readily transfer and/or resell your security. Currently there is no market or liquidity for these shares and the Company does not have any plans to list these shares on an exchange or other secondary market. At some point the Company may choose to do so, but until then you should plan to hold your investment for a significant period of time before a 'liquidation event' occurs. A 'liquidation event' is when the Company either lists their shares on an exchange, is acquired, or goes bankrupt.
7. 10. Valuation and capitalization. Unlike listed companies that are valued publicly through market-driven stock prices, the valuation of private companies, especially startups, is difficult to assess and you may risk overpaying for your investment. In addition, there may be additional classes of equity with rights that are superior to the class of equity being sold.
8. 11. You may only receive limited disclosure. While the Company must disclose certain information, since the Company is at an early-stage they may only be able to provide limited information about its business plan and operations because it does not have fully developed operations or a long history. The Company may also only be obligated to file information periodically regarding its business, including financial statements. A publicly listed company, in contrast, is required to file annual and quarterly reports and promptly disclose certain events - through continuing disclosure that you can use to evaluate the status of your investment.
9. 12. Lack of professional guidance. Many successful companies partially attribute their early success to the guidance of professional early-stage investors (e.g., angel investors and venture capital firms). These investors often negotiate for seats on the Company's board of directors and play an important role through their resources, contacts and experience in assisting early-stage companies in executing on their business plans. An early-stage company may not have the benefit of such professional investors.

13. Third parties might infringe upon our technology. We cannot assure you that the steps we have taken to protect our property rights will prevent misappropriation of our technology. To protect our rights to our intellectual property, we plan to rely on a combination of trade secrets, confidentiality agreements and other contractual arrangements with our employees, affiliates, strategic partners and others. We may be unable to detect inappropriate use of our technology. Failure to adequately protect our intellectual property could materially harm our brand, devalue our proprietary content and affect our ability to compete effectively. Further, defending any technology rights could result in significant financial expenses and managerial resources.
14. We may be unable to generate significant revenues and may never become profitable. We generated no revenue for the years ended December 31, 2021 and 2020 and do not currently have any material recurring sources of revenues, making it difficult to predict when we will be profitable. We expect to incur significant research and development costs for the foreseeable future. We may not be able to successfully market our products and services in the future that will generate significant revenues. In addition, any revenues that we may generate may be insufficient for us to become profitable.
15. *The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature.*

You should not rely on the fact that our Form C, and if applicable Form D is accessible through the U.S. Securities and Exchange Commission's EDGAR filing system as an approval, endorsement or guarantee of compliance as it relates to this Offering.

16. *Neither the Offering nor the Securities have been registered under federal or state securities laws, leading to an absence of certain regulation applicable to the Company.*

The securities being offered have not been registered under the Securities Act of 1933 (the "Securities Act"), in reliance on exemptive provisions of the Securities Act. Similar reliance has been placed on apparently available exemptions from securities registration or qualification requirements under applicable state securities laws. No assurance can be given that any offering currently qualifies or will continue to qualify under one or more of such exemptive provisions due to, among other things, the adequacy of disclosure and the manner of distribution, the existence of similar offerings in the past or in the future, or a change of any securities law or regulation that has retroactive effect. If, and to the extent that, claims or suits for rescission are brought and successfully concluded for failure to register any offering or other offerings or for acts or omissions constituting offenses under the Securities Act, the Securities Exchange Act of 1934, or applicable state securities laws, the Company could be materially adversely affected, jeopardizing the Company's ability to operate successfully. Furthermore, the human and capital resources of the Company could be adversely affected by the need to defend actions under these laws, even if the Company is ultimately successful in its defense.

17. *The Company has the right to extend the Offering Deadline, conduct multiple closings, or end the Offering early.*

The Company may extend the Offering Deadline beyond what is currently stated herein. This means that your investment may continue to be held in escrow while the Company attempts to raise the Minimum Amount even after the Offering Deadline stated herein is reached. While you have the right to cancel your investment up to 48 hours before an Offering Deadline, if you choose to not cancel your investment, your investment will not be accruing interest during this time and will simply be held until such time as the new Offering Deadline is reached without the Company receiving the Minimum Amount, at which time it will be returned to you without interest or deduction, or the Company receives the Minimum Amount, at which time it will be released to the Company to be used as set forth herein. Upon or shortly after release of such funds to the Company, the Securities will be issued and distributed to you. If the Company reaches the target offering amount prior to the Offering Deadline, they may conduct the first of multiple closings of the Offering prior to the Offering Deadline, provided that the Company gives notice to the investors of the closing at least five business

days prior to the closing (absent a material change that would require an extension of the Offering and reconfirmation of the investment commitment). Thereafter, the Company may conduct additional closings until the Offering Deadline. The Company may also end the Offering early; if the Offering reaches its target offering amount after 21-calendar days but before the deadline, the Company can end the Offering with 5 business days' notice. This means your failure to participate in the Offering in a timely manner, may prevent you from being able to participate - it also means the Company may limit the amount of capital it can raise during the Offering by ending it early.

18. *The Company's management may have broad discretion in how the Company uses the net proceeds of the Offering.*

Despite that the Company has agreed to a specific use of the proceeds from the Offering, the Company's management will have considerable discretion over the allocation of proceeds from the Offering. You may not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.

19. *The Securities issued by the Company will not be freely tradable until one year from the initial purchase date. Although the Securities may be tradable under federal securities law, state securities regulations may apply, and each Investor should consult with his or her attorney.*

You should be aware of the long-term nature of this investment. There is not now and likely will not be a public market for the Securities. Because the Securities offered in this Offering have not been registered under the Securities Act or under the securities laws of any state or non-United States jurisdiction, the Securities have transfer restrictions and cannot be resold in the United States except pursuant to Rule 501 of Regulation CF. It is not currently contemplated that registration under the Securities Act or other securities laws will be affected. Limitations on the transfer of the shares of Securities may also adversely affect the price that you might be able to obtain for the shares of Securities in a private sale. Investors should be aware of the long-term nature of their investment in the Company. Investors in this Offering will be required to represent that they are purchasing the Securities for their own account, for investment purposes and not with a view to resale or distribution thereof.

20. *Investors will not be entitled to any inspection or information rights other than those required by Regulation CF.*

Investors will not have the right to inspect the books and records of the Company or to receive financial or other information from the Company, other than as required by Regulation CF. Other security holders of the Company may have such rights. Regulation CF requires only the provision of an annual report on Form C and no additional information - there are numerous methods by which the Company can terminate annual report obligations, resulting in no information rights, contractual, statutory or otherwise, owed to Investors. This lack of information could put Investors at a disadvantage in general and with respect to other security holders.

21. *The shares of Securities acquired upon the Offering may be significantly diluted as a consequence of subsequent financings.*

Company equity securities will be subject to dilution. Company intends to issue additional equity to future employees and third-party financing sources in amounts that are uncertain at this time, and as a consequence, holders of Securities will be subject to dilution in an unpredictable amount. Such dilution may reduce the purchaser's economic interests in the Company.

22. The amount of additional financing needed by Company will depend upon several contingencies not foreseen at the time of this Offering. Each such round of financing (whether from the Company or other investors) is typically intended to provide the Company with enough capital to reach the next

major corporate milestone. If the funds are not sufficient, Company may have to raise additional capital at a price unfavorable to the existing investors. The availability of capital is at least partially a function of capital market conditions that are beyond the control of the Company. There can be no assurance that the Company will be able to predict accurately the future capital requirements necessary for success or that additional funds will be available from any source. Failure to obtain such financing on favorable terms could dilute or otherwise severely impair the value of the investor's Company securities.

23. *There is no present public market for these Securities and we have arbitrarily set the price.*

The offering price was not established in a competitive market. We have arbitrarily set the price of the Securities with reference to the general status of the securities market and other relevant factors. The Offering price for the Securities should not be considered an indication of the actual value of the Securities and is not based on our net worth or prior earnings. We cannot assure you that the Securities could be resold by you at the Offering price or at any other price.

24. In addition to the risks listed above, businesses are often subject to risks not foreseen or fully appreciated by the management. It is not possible to foresee all risks that may affect us. Moreover, the Company cannot predict whether the Company will successfully effectuate the Company's current business plan. Each prospective Investor is encouraged to carefully analyze the risks and merits of an investment in the Securities and should take into consideration when making such analysis, among other, the Risk Factors discussed above.

25. THE SECURITIES OFFERED INVOLVE A HIGH DEGREE OF RISK AND MAY RESULT IN THE LOSS OF YOUR ENTIRE INVESTMENT. ANY PERSON CONSIDERING THE PURCHASE OF THESE SECURITIES SHOULD BE AWARE OF THESE AND OTHER FACTORS SET FORTH IN THIS OFFERING STATEMENT AND SHOULD CONSULT WITH HIS OR HER LEGAL, TAX AND FINANCIAL ADVISORS PRIOR TO MAKING AN INVESTMENT IN THE SECURITIES. THE SECURITIES SHOULD ONLY BE PURCHASED BY PERSONS WHO CAN AFFORD TO LOSE ALL OF THEIR INVESTMENT.

## The Offering

Addiction Cure Therapeutic Sciences Inc ('Company') is offering securities under Regulation CF, through Netcapital Funding Portal Inc. ('Portal'). Portal is a FINRA/SEC registered funding portal and will receive cash compensation equal to 4.9% of the value of the securities sold through Regulation CF. Investments made under Regulation CF involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest.

The Company plans to raise between $10,000 and $1,070,000 through an offering under Regulation CF. Specifically, if we reach the target offering amount of $10,000, we may conduct the first of multiple or rolling closings of the offering early if we provide notice about the new offering deadline at least five business days prior to such new offering deadline (absent a material change that would require an extension of the offering and reconfirmation of the investment commitment). Oversubscriptions will be allocated on a first come, first served basis. Changes to the offering, material or otherwise, occurring after a closing, will only impact investments which have yet to be closed.

In the event The Company fails to reach the offering target of $10,000, any investments made under the offering will be cancelled and the investment funds will be returned to the investor.

# **8. What is the purpose of this offering?**

We plan to use the proceeds from this offering primarily on lab compound testing, officer salaries, and general and administrative expenses.

# **9. How does the issuer intend to use the proceeds of this offering?**

| Uses | If Target Offering Amount Sold | If Maximum Amount Sold |
| --- | --- | --- |
| Intermediary Fees | $490 | $52,430 |
| Lab Compound Testing | $9,510 | $560,000 |
| Research and Development | $0 | $52,570 |
| Officer Salaries | $0 | $156,000 |
| G&A (rent, utilities, insurance payments, wages and salaries for administrative and other staff) | $0 | $90,000 |
| Social Media Director | $0 | $45,000 |
| Grant Writer | $0 | $60,000 |
| Marketing | $0 | $45,000 |
| Travel/Trade Shows | $0 | $9,000 |
| Total Use of Proceeds | $10,000 | $1,070,000 |

# **10. How will the issuer complete the transaction and deliver securities to the investors?**

In entering into an agreement on the Netcapital Funding Portal to purchase securities, both investors and Addiction Cure Therapeutic Sciences Inc must agree that a transfer agent, which keeps records of our outstanding Common Stock (the 'Securities'), will issue digital Securities in the investor's name (a paper certificate will not be printed). Similar to other online investment accounts, the transfer agent will give investors access to a web site to see the number of Securities that they own in our company. These Securities will be issued to investors after the deadline date for investing has passed, as long as the targeted offering amount has been reached. The transfer agent will record the issuance when we have received the purchase proceeds from the escrow agent who is holding your investment commitment.

# **11. How can an investor cancel an investment commitment?**

You may cancel an investment commitment for any reason until 48 hours prior to the deadline identified in the offering by logging in to your account with Netcapital, browsing to the Investments screen, and clicking to cancel your investment commitment. Netcapital will notify investors when the target offering amount has been met. If the issuer reaches the target offering amount prior to the deadline identified in the offering materials, it may close the offering early if it provides notice about the new offering deadline at least five business days prior to such new offering deadline (absent a material change that would require an extension of the offering and reconfirmation of the investment commitment). If an investor does not cancel an investment commitment before the 48-hour period prior to the offering deadline, the funds will be released to the issuer upon closing of the offering and the investor will receive securities in exchange for his or her investment. If an investor does not reconfirm his or her investment commitment after a material change is made to the offering, the investor's investment commitment will be cancelled and the committed funds will be returned.

# **12. Can the Company perform multiple closings or rolling closings for the offering?**

If we reach the target offering amount prior to the offering deadline, we may conduct the first of multiple closings of the offering early, if we provide notice about the new offering deadline at least five business days prior (absent a material change that would require an extension of the offering and reconfirmation of the investment commitment). Thereafter, we may conduct additional closings until the offering deadline. We will issue Securities in connection with each closing. Oversubscriptions will be allocated on a first come, first served basis. Changes to the offering, material or otherwise, occurring after a closing, will only impact investments which have yet to be closed.

## Ownership and Capital Structure

### The Offering

#### 13. Describe the terms of the securities being offered.

We are issuing Securities at an offering price of $0.50 per share.

#### 14. Do the securities offered have voting rights?

The Securities are being issued with voting rights. However, so that the crowdfunding community has the opportunity to act together and cast a vote as a group when a voting matter arises, a record owner will cast your vote for you. Please refer to the record owner agreement that you sign before your purchase is complete.

#### 15. Are there any limitations on any voting or other rights identified above?

You are giving your voting rights to the record owner, who will vote the Securities on behalf of all investors who purchased Securities on the Netcapital crowdfunding portal.

#### 16. How may the terms of the securities being offered be modified?

We may choose to modify the terms of the securities before the offering is completed. However, if the terms are modified, and we deem it to be a material change, we need to contact you and you will be given the opportunity to reconfirm your investment. Your reconfirmation must be completed within five business days of receipt of the notice of a material change, and if you do not reconfirm, your investment will be canceled and your money will be returned to you.

### Restrictions on Transfer of the Securities Offered

The securities being offered may not be transferred by any purchaser of such securities during the one-year period beginning when the securities were issued, unless such securities are transferred:

- to the issuer;
- to an accredited investor;
- as part of an offering registered with the U.S. Securities and Exchange Commission; or
- to a member of the family of the purchaser or the equivalent, to a trust controlled by the purchaser, to a trust created for the benefit of a member of the family of the purchaser or the equivalent, or in connection with the death or divorce of the purchaser or other similar circumstance.

The term “accredited investor” means any person who comes within any of the categories set forth in Rule 501(a) of Regulation D, or who the seller reasonably believes comes within any of such categories, at the

time of the sale of the securities to that person.

The term “member of the family of the purchaser or the equivalent” includes a child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spousal equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law of the purchaser, and includes adoptive relationships. The term “spousal equivalent” means a cohabitant occupying a relationship generally equivalent to that of a spouse.

## Description of Issuer’s Securities

17. What other securities or classes of securities of the issuer are outstanding? Describe the material terms of any other outstanding securities or classes of securities of the issuer.

### Securities

| Class of Security | Amount Authorized | Amount Outstanding | Voting Rights | Other Rights |
| --- | --- | --- | --- | --- |
| Preferred Stock | 2,000 | 2,000 | Yes | 5,000 votes per share. |
| Common Stock | 20,000,000 | 12,100,000 | Yes | One vote per share. |

### Options, Warrants and Other Rights

| Type | Description | Reserved Securities |
| --- | --- | --- |
| Option Grant 1 | 5-year option issued to Lui Delgado June 26, 2022, expiring June 25, 2027, with a 50-cent exercise price. | 100,000 |
| Option Grant 2 | 5-year option issued to Michael Levine June 26, 2022, expiring June 25, 2027, with a 50-cent exercise price. | 200,000 |
| Option Grant 3 | 5-year option issued to Kevin Murnane June 26, 2022, expiring June 25, 2027, with a 50-cent exercise price. | 100,000 |
| Option Grant 4 | 5-year option issued to Wayne Gill June 26, 2022, expiring June 25, 2027, with a 50-cent exercise price. | 200,000 |
| Option Grant 5 | 5-year option issued to Bruce Roth June 26, 2022, expiring June 25, 2027, with a 50-cent exercise price. | 200,000 |
| Option Grant 6 | 5-year option issued to Glenn Grossman June 26, 2022, expiring June 25, 2027, with a 50-cent exercise price. | 200,000 |
| Option Grant 7 | 5-year option issued to Rick Garcia June 26, 2022, expiring June 25, 2027, with a 50-cent exercise price. | 200,000 |
| Option Grant 8 | 5-year option issued to Jonas Masreliez June 26, 2022, expiring June 25, 2027, with a 50-cent exercise price. | 5,000 |
| Option Grant 9 | Options to purchase up to 1,700,000 shares of common stock at an exercise price of $0.001 for Y LINE LLC (CMO Rick Garcia). Options vest on August 1, 2023, so long as Y LINE LLC is a service provider to the Company at that time. Options expire on September 1, 2023. | 1,700,000 |
| Option Grant 10 | Options to purchase up to 1,700,000 shares of common stock at an exercise price of $0.001 for Y LINE LLC (CMO Rick Garcia). Options vest on August 1, 2024, so long as Y LINE LLC is a service provider to the Company at that time. Options expire on September 1, 2024. | 1,700,000 |

# **18. How may the rights of the securities being offered be materially limited, diluted or qualified by the rights of any other class of securities?**

During 2022, the Company issued 1,205,000 stock options to various advisors of the Company. The options expire in June 2027. Additionally, the Company issued 3,400,000 options to Y LINE LLC (CMO Rick Garcia). If any of these options were to be exercised into issued shares, your equity would be diluted.

# **19. Are there any differences not reflected above between the securities being offered and each other class of security of the issuer?**

The Company has granted a perpetual waiver of the transfer restrictions listed in the Bylaws of Addiction Cure Therapeutic Sciences Inc for all Securities sold in this Offering.

**20. How could the exercise of rights held by the principal owners identified in Question 5 above affect the purchasers of Securities being offered?**

The Company's bylaws can be amended by the shareholders of the Company, and directors can be added or removed by shareholder vote. As minority owners, you are subject to the decisions made by the majority owners. The issued and outstanding common stock gives management voting control of the Company. As a minority owner, you may be outvoted on issues that impact your investment, such as the issuance of additional shares, or the sale of debt, convertible debt or assets of the Company.

**21. How are the securities being offered being valued? Include examples of methods for how such securities may be valued by the issuer in the future, including during subsequent corporate actions.**

The price of the Securities was determined solely by the management and bears no relation to traditional measures of valuation such as book value or price-to-earnings ratios. We expect that any future valuation will take the same approach.

**22. What are the risks to purchasers of the securities relating to minority ownership in the issuer?**

As the holder of a majority of the voting rights in the Company, our majority shareholders may make decisions with which you disagree, or that negatively affect the value of your investment in the Company, and you will have no recourse to change those decisions. Your interests may conflict with the interests of other investors, and there is no guarantee that the Company will develop in a way that is advantageous to you. For example, the majority shareholders may decide to issue additional shares to new investors, sell convertible debt instruments with beneficial conversion features, or make decisions that affect the tax treatment of the Company in ways that may be unfavorable to you. Based on the risks described above, you may lose all or part of your investment in the securities that you purchase, and you may never see positive returns.

**23. What are the risks to purchasers associated with corporate actions including:**

- additional issuances of securities,
- issuer repurchases of securities,
- a sale of the issuer or of assets of the issuer or
- transactions with related parties?

The issuance of additional shares of our common stock will dilute your ownership. As a result, if we achieve profitable operations in the future, our net income per share will be reduced because of dilution, and the market price of our common stock, if there is a market price, could decline as a result of the additional issuances of securities. If we repurchase securities, so that the above risk is mitigated, and there are fewer shares of common stock outstanding, we may not have enough cash available for marketing expenses, growth, or operating expenses to reach our goals. If we do not have enough cash to operate and grow, we anticipate the market price of our stock would decline. A sale of our company or of the assets of our company may result in an entire loss of your investment. We cannot predict the market value of our company or our assets, and the proceeds of a sale may not be cash, but instead, unmarketable securities, or an assumption of liabilities. In addition to the payment of wages and expense reimbursements, we may need to engage in transactions with officers, directors, or affiliates. By acquiring an interest in the Company, you will be deemed to have acknowledged the existence of any such actual or potential related party transactions and waived any claim with respect to any liability arising from a perceived or actual conflict of interest. In some instances, we may deem it necessary to seek a loan from related parties. Such financing may not be available when needed. Even if such financing is available, it may be on terms that are materially averse to your interests with respect to dilution of book value, dividend preferences, liquidation preferences, or other terms. No assurance can be given that such funds will be available or, if available, will be on commercially reasonable terms satisfactory to us. If we are unable to obtain financing on reasonable terms, we could be forced to discontinue our operations. We anticipate that any transactions with related parties will be vetted and approved by executives(s) unaffiliated with the related parties.

# **24. Describe the material terms of any indebtedness of the issuer:**

| Creditor(s): | Jack Levine |
| --- | --- |
| Amount Outstanding: | $9,925 |
| Interest Rate: | 0.0% |
| Maturity Date: | Payable On Demand |
| Other Material Terms: | None |

# **25. What other exempt offerings has Addiction Cure Therapeutic Sciences Inc conducted within the past three years?**

| Date of Offering: | 12/2021 |
| --- | --- |
| Exemption: | Rule 701 |
| Securities Offered: | Common Stock |
| Amount Sold: | $9,850 |
| Use of Proceeds: | 9,850,000 shares of common stock were issued in the form of stock compensation. No cash was received in this transaction. |
| Date of Offering: | 12/2020 |
| Exemption: | Rule 701 |
| Securities Offered: | Common Stock |
| Amount Sold: | $150 |
| Use of Proceeds: | 150,000 shares of common stock were issued in the form of stock compensation. No cash was received in this transaction. |
| Date of Offering: | 12/2021 |
| Exemption: | Rule 701 |
| Securities Offered: | Preferred Stock |
| Amount Sold: | $2 |
| Use of Proceeds: | 2,000 shares of preferred stock were issued in the form of stock compensation. No cash was received in this transaction. |
| Date of Offering: | 01/2022 |
| Exemption: | Rule 701 |
| Securities Offered: | Common Stock |
| Amount Sold: | $2,050 |
| Use of Proceeds: | 2,050,000 shares of common stock were issued in the form of stock compensation to the CEO. No cash was received in this transaction. |
| Date of Offering: | 08/2022 |
| Exemption: | Reg. D, Rule 506(b) |
| Securities Offered: | Common Stock |
| Amount Sold: | $12,500 |

**Use of Proceeds:**

The proceeds were used to hire law firm to review contracts from LSU for lab work and draft joint venture agreements and other legal documents.

26. Was or is the issuer or any entities controlled by or under common control with the issuer a party to any transaction since the beginning of the issuer's last fiscal year, or any currently proposed transaction, where the amount involved exceeds five percent of the aggregate amount of capital raised by the issuer in reliance on Section 4(a)(6) of the Securities Act during the preceding 12-month period, including the amount the issuer seeks to raise in the current offering, in which any of the following persons had or is to have a direct or indirect material interest:
1. any director or officer of the issuer;
2. any person who is, as of the most recent practicable date, the beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, calculated on the basis of voting power;
3. if the issuer was incorporated or organized within the past three years, any promoter of the issuer; or
4. any immediate family member of any of the foregoing persons.

No.

## Financial Condition of the Issuer

27. Does the issuer have an operating history?

Yes.

28. Describe the financial condition of the issuer, including, to the extent material, liquidity, capital resources and historical results of operations.

Addiction Cure Therapeutic Sciences, Inc. (the "Company") was incorporated on April 28, 2020 under the laws of Florida. The Company intends to operate as a biotech firm that develops therapeutic products to treat and cure drug and alcohol addiction. Pursuant to the Company's amended articles of incorporation, the Company is authorized to issue 20,000,000 shares of common stock at $0.001 par value per share and 2,000 shares of preferred stock at $0.001 par value per share. As of the date of filing of this offering the Company had 12,100,000 shares of common stock and 2,000 shares of preferred stock issued and outstanding. The holder of each share of common stock is entitled to one vote per share and the holder of each share of preferred stock is entitled to 5,000 votes per share. The voting, dividend, and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers, and preferences of the holders of the preferred stock. The Company is still in its pre-revenue stage. During 2022, the Company raised $12,500 by issuing 50,000 shares of common stock through a Reg D Offering. The proceeds were spent primarily on hiring a law firm to review contracts from LSU for lab work and draft joint venture agreements. In addition, 2,050,000 shares of common stock were issued in the form of stock compensation to the CEO. No cash was received in this transaction. During the same fiscal year, the Company issued 1,205,000 stock options to various advisors of the Company. The options expire in June 2027. Moreover, the Company issued 3,400,000 options to Y LINE LLC (CMO Rick Garcia). During the year ended December 31, 2021, the Company had operating expenses of $2,716 resulting in a net loss for the year of $2,716. During the year ended December 31, 2020, the Company had operating expenses of $10,002, resulting in a net loss for the year of $10,002. During 2021, the Company received $3,579 in cash in the form of a stockholder advance, increasing the balance owed from $150 to $3,729. During the first 8 months of 2022, the Company received an additional $6,196 in cash in the form of a stockholder advance, increasing the balance owed to $9,925. The stockholder advance does not bear interest and is payable on demand to CEO Jack Levine. With this raise, the Company plans to spend the money primarily on lab compound testing, officer salaries, and general and administrative.

# Financial Information

29. Include the financial information specified by regulation, covering the two most recently completed fiscal years or the period(s) since inception if shorter.

See attachments:

CPA Review Report:

reviewletter.pdf

30. With respect to the issuer, any predecessor of the issuer, any affiliated issuer, any director, officer, general partner or managing member of the issuer, any beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, calculated in the same form as described in Question 6 of this Question and Answer format, any promoter connected with the issuer in any capacity at the time of such sale, any person that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with such sale of securities, or any general partner, director, officer or managing member of any such solicitor, prior to May 16, 2016:

1. Has any such person been convicted, within 10 years (or five years, in the case of issuers, their predecessors and affiliated issuers) before the filing of this offering statement, of any felony or misdemeanor:
1. in connection with the purchase or sale of any security?
2. involving the making of any false filing with the Commission?
3. arising out of the conduct of the business of an underwriter, broker, dealer, municipal securities dealer, investment adviser, funding portal or paid solicitor of purchasers of securities?

2. Is any such person subject to any order, judgment or decree of any court of competent jurisdiction, entered within five years before the filing of the information required by Section 4A(b) of the Securities Act that, at the time of filing of this offering statement, restrains or enjoins such person from engaging or continuing to engage in any conduct or practice:
1. in connection with the purchase or sale of any security?;
2. involving the making of any false filing with the Commission?
3. arising out of the conduct of the business of an underwriter, broker, dealer, municipal securities dealer, investment adviser, funding portal or paid solicitor of purchasers of securities?

3. Is any such person subject to a final order of a state securities commission (or an agency or officer of a state performing like functions); a state authority that supervises or examines banks, savings associations or credit unions; a state insurance commission (or an agency or officer of a state performing like functions); an appropriate federal banking agency; the U.S. Commodity Futures Trading Commission; or the National Credit Union Administration that:
1. at the time of the filing of this offering statement bars the person from:
1. association with an entity regulated by such commission, authority, agency or officer?
2. engaging in the business of securities, insurance or banking?
3. engaging in savings association or credit union activities?

2. constitutes a final order based on a violation of any law or regulation that prohibits fraudulent, manipulative or deceptive conduct and for which the order was entered within the 10-year period ending on the date of the filing of this offering statement?

4. Is any such person subject to an order of the Commission entered pursuant to Section 15(b) or 15B(c) of the Exchange Act or Section 203(e) or (f) of the Investment Advisers Act of 1940 that, at the time of the filing of this offering statement:
1. suspends or revokes such person's registration as a broker, dealer, municipal securities dealer, investment adviser or funding portal?
2. places limitations on the activities, functions or operations of such person?
3. bars such person from being associated with any entity or from participating in the offering of any penny stock?

If Yes to any of the above, explain:

5. Is any such person subject to any order of the Commission entered within five years before the filing of this offering statement that, at the time of the filing of this offering statement, orders the person to cease and desist from committing or causing a violation or future violation of:

1. any scienter-based anti-fraud provision of the federal securities laws, including without limitation Section 17(a)(1) of the Securities Act, Section 10(b) of the Exchange Act, Section 15(c)(1) of the Exchange Act and Section 206(1) of the Investment Advisers Act of 1940 or any other rule or regulation thereunder?
2. Section 5 of the Securities Act?
6. Is any such person suspended or expelled from membership in, or suspended or barred from association with a member of, a registered national securities exchange or a registered national or affiliated securities association for any act or omission to act constituting conduct inconsistent with just and equitable principles of trade?
7. Has any such person filed (as a registrant or issuer), or was any such person or was any such person named as an underwriter in, any registration statement or Regulation A offering statement filed with the Commission that, within five years before the filing of this offering statement, was the subject of a refusal order, stop order, or order suspending the Regulation A exemption, or is any such person, at the time of such filing, the subject of an investigation or proceeding to determine whether a stop order or suspension order should be issued?
8. Is any such person subject to a United States Postal Service false representation order entered within five years before the filing of the information required by Section 4A(b) of the Securities Act, or is any such person, at the time of filing of this offering statement, subject to a temporary restraining order or preliminary injunction with respect to conduct alleged by the United States Postal Service to constitute a scheme or device for obtaining money or property through the mail by means of false representations?

Addiction Cure Therapeutic Sciences Inc answers 'NO' to all of the above questions.

## Other Material Information

31. In addition to the information expressly required to be included in this Form, include: any other material information presented to investors; and such further material information, if any, as may be necessary to make the required statements, in the light of the circumstances under which they are made, not misleading.

The following is a transcript of the Company's video on their Page. Addiction Cure Therapeutic Sciences Inc. (ACTS) is a biotech firm advancing in class therapeutics to potentially treat and cure the devastating disease of drug and alcohol addiction. The company plans to develop Rx products designed to provide a functional cure for addiction, as the need for a cure is eminent and immense. According to the National Survey on Drug Use and Health (NSDUH), 21 million American adults are battling a substance use disorder, only 10% receive treatment, and this number is growing faster each year. Our team of scientists, researchers and business leaders are simultaneously working on multiple novel theories using epigenetics, endocannabinoids, and other unique combinations of molecules and compounds that have shown early promise and positive results. The need is immense, our Team is in place, and the pathway to a cure is clear...ACTS plans to pursue multiple theories and to work with numerous scientists and different Labs and Academic Institutions. ACTS' entire purpose is to find a chemical cure for chemical addiction, envisioning finally bringing an end to the life destroying scourge of drug and alcohol addiction.

The following documents are being submitted as part of this offering:

Governance:

Certificate of Incorporation: certificateofincorporation.pdf

Corporate Bylaws: corporatebylaws.pdf

Opportunity:

Offering Data, INC: offeringdata.com

| Offering Page JPG: | offeringpage.jpg |
| --- | --- |
| Financials: |  |
| Additional Information: | otherfinancial.pdf |

## Ongoing Reporting

32. The issuer will file a report electronically with the Securities & Exchange Commission annually and post the report on its web site, no later than 120 days after the end of each fiscal year covered by the report:

Once posted, the annual report may be found on the issuer's web site at: https://www.addictioncuretherapeuticsciences.com/

The issuer must continue to comply with the ongoing reporting requirements until:

- the issuer is required to file reports under Section 13(a) or Section 15(d) of the Exchange Act;
- the issuer has filed at least one annual report pursuant to Regulation Crowdfunding and has fewer than 300 holders of record and has total assets that do not exceed $10,000,000;
- the issuer has filed at least three annual reports pursuant to Regulation Crowdfunding;
- the issuer or another party repurchases all of the securities issued in reliance on Section 4(a)(6) of the Securities Act, including any payment in full of debt securities or any complete redemption of redeemable securities; or
- the issuer liquidates or dissolves its business in accordance with state law.

**Attachment 2:** `reviewletter.pdf`

# Addiction Cure Therapeutic Sciences, Inc.

Financial Statements (Unaudited)

December 31, 2021 and 2020

![img-0.jpeg](img-0.jpeg)

4401 Dominion Boulevard
Glen Allen, Virginia 23060
Tel: 804.747.0000
www.keitercpa.com

# **ADDICTION CURE THERAPEUTIC SCIENCES, INC.**

# Table of Contents

|  | Page |
| --- | --- |
| Report of Independent Accountants | 1 |
| Financial Statements: |  |
| Balance Sheets | 2 |
| Statements of Operations | 3 |
| Statements of Changes in Stockholders' Equity (Deficit) | 4 |
| Statements of Cash Flows | 5 |
| Notes to Financial Statements | 6 |

Keiter
Your Opportunity Advisors

# REPORT OF INDEPENDENT ACCOUNTANTS

To the Stockholders
Addiction Cure Therapeutic Sciences, Inc.
Coconut Creek, Florida

We have reviewed the accompanying financial statements of Addiction Cure Therapeutic Sciences, Inc. (the "Company"), which comprise the balance sheets as of December 31, 2021 and 2020, and the related statements of operations, changes in stockholders' equity (deficit), and cash flows for the year ended December 31, 2021 and for the period from April 28, 2020 (inception) through December 31, 2020, and the related notes to the financial statements. A review includes primarily applying analytical procedures to management's financial data and making inquiries of Company management. A review is substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the financial statements as a whole. Accordingly, we do not express such an opinion.

# Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement whether due to fraud or error.

# Accountant's Responsibility

Our responsibility is to conduct the review engagements in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. Those standards require us to perform procedures to obtain limited assurance as a basis for reporting whether we are aware of any material modifications that should be made to the financial statements for them to be in accordance with accounting principles generally accepted in the United States. We believe that the results of our procedures provide a reasonable basis for our conclusion.

We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements related to our reviews.

# Accountant's Conclusion

Based on our reviews, we are not aware of any material modifications that should be made to the accompanying financial statements in order for them to be in accordance with accounting principles generally accepted in the United States.

August 17, 2022
Glen Allen, Virginia

> Certified Public
Accountants & Consultants
4401 Dominion Boulevard
Glen Allen, VA 23060
T:804.747.0000 F:804.747.3632

www.keitercpa.com

# **ADDICTION CURE THERAPEUTIC SCIENCES, INC.**

Balance Sheets (unaudited)
December 31, 2021 and 2020

| Assets | 2021 | 2020 |
| --- | --- | --- |
| Current assets: |  |  |
| Cash | $1,013 | $ - |
| Total assets | $1,013 | $ - |
| Liabilities and Stockholders' Deficit |  |  |
| Current liabilities: |  |  |
| Advances - stockholder | $3,729 | $150 |
| Stockholders' deficit: |  |  |
| Common stock $0.001 par value; 20,000,000 shares authorized; 10,000,000 shares issued and outstanding at December 31, 2021 and 10,000,000 shares authorized; 9,850,000 shares issued and outstanding at December 31, 2020 | 10,000 | 9,850 |
| Preferred stock $0.001 par value; 2,000 shares authorized; 2,000 shares issued and outstanding at December 31, 2021 and 2020 | 2 | 2 |
| Accumulated deficit | (12,718) | (10,002) |
| Total stockholders' deficit | (2,716) | (150) |
| Total liabilities and stockholders' deficit | $1,013 | $ - |

See report of independent accountants and accompanying notes to financial statements.

2

# **ADDICTION CURE THERAPEUTIC SCIENCES, INC.**

Statements of Operations (unaudited)  
Year Ended December 31, 2021 and for the period from  
April 28, 2020 (inception) through December 31, 2020

|  | 2021 | 2020 |
| --- | --- | --- |
| Revenue | $ - | $ - |
| Operating expenses | 2,716 | 10,002 |
| Net loss | $(2,716) | $(10,002) |

See report of independent accountants and accompanying notes to financial statements.

3

# **ADDICTION CURE THERAPEUTIC SCIENCES, INC.**

Statements of Changes in Stockholders' Equity (Deficit) (unaudited)  
 Year Ended December 31, 2021 and for the period from  
 April 28, 2020 (inception) through December 31, 2020

|  | Common Stock | Preferred Stock | Accumulated Deficit | Total |
| --- | --- | --- | --- | --- |
| Balance, April 28, 2020 | $ - | $ - | $ - | $ - |
| Issuance of stock | 9,850 | 2 | - | 9,852 |
| Net loss | - | - | (10,002) | (10,002) |
| Balance, December 31, 2020 | 9,850 | 2 | (10,002) | (150) |
| Issuance of stock | 150 | - | - | 150 |
| Net loss | - | - | (2,716) | (2,716) |
| Balance, December 31, 2021 | $10,000 | $2 | $(12,718) | $(2,716) |

See report of independent accountants and accompanying notes to financial statements.

4

# **ADDICTION CURE THERAPEUTIC SCIENCES, INC.**

Statements of Cash Flows (unaudited)  
 Year Ended December 31, 2021 and for the period from  
 April 28, 2020 (inception) through December 31, 2020

|  | 2021 | 2020 |
| --- | --- | --- |
| Cash flows from operating activities: |  |  |
| Net loss | $(2,716) | $(10,002) |
| Adjustments to reconcile net loss to net cash from operating activities: |  |  |
| Stock compensation | 150 | 9,852 |
| Net cash used in operating activities | (2,566) | (150) |
| Cash flows provided by financing activities: |  |  |
| Proceeds from stockholder advances | 3,579 | 150 |
| Net change in cash | 1,013 | - |
| Cash, beginning of period | - | - |
| Cash, end of period | $1,013 | $ - |
| Supplemental disclosure of non-cash transactions: |  |  |
| Stock issued for stock compensation | $150 | $9,852 |

See report of independent accountants and accompanying notes to financial statements.

5

# ADDICTION CURE THERAPEUTIC SCIENCES, INC.

### Notes to Financial Statements (unaudited)

#### 1. Summary of Significant Accounting Policies:

**Nature of Business:** Addiction Cure Therapeutic Sciences, Inc. (the 'Company') was incorporated on April 28, 2020 in the State of Florida. The Company intends to operate as a biotech firm that develops therapeutic products to treat and cure drug and alcohol addiction.

**Management's Plans:** The Company's updated strategic plan for 2022 and beyond is focused on funding laboratory tests with recognized research labs or promising epigenetic and endocannabinoid compounds it has already identified as potential addiction cures based on the expertise of its scientists, board and advisory board members. By the Company raising capital this will enable it to continue its plan to attract additional scientists and work with key researchers and laboratories, as well as grow the Company's social media presence via marketing, with the goal of searching for and finding a cure to bring to market. The Company believes that through its crowdfunding efforts and other investor support it will be able to raise additional capital to support the testing of its first two compounds and operate for a reasonable period of time.

**Basis of Accounting:** The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States ('GAAP') as determined by the Financial Accounting Standards Board ('FASB') Accounting Standards Codification ('ASC').

**Use of Estimates:** The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

**Income Taxes:** The Company's deferred income taxes are provided on temporary differences between financial statement and income tax reporting. Temporary differences are differences between the amounts of assets and liabilities reported for financial statement purposes and their tax basis. Deferred tax assets are recognized for temporary differences that will be deductible in future years' tax returns and for operating loss and tax credit carryforwards. Deferred tax assets are reduced by a valuation allowance if it is deemed more likely than not that some or all of the deferred tax assets will not be realized. Deferred tax liabilities are recognized for temporary differences that will be taxable in future years' tax returns.

**Income Tax Uncertainties:** The Company follows FASB guidance for how uncertain tax positions should be recognized, measured, disclosed and presented in the financial statements. This requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company's tax returns to determine whether the tax positions are 'more-likely-than-not' of being sustained 'when challenged' or 'when examined' by the applicable tax authority. Tax positions not deemed to meet the more-likely-than-not threshold would be recorded as a tax expense and liability in the current year.

6

# ADDICTION CURE THERAPEUTIC SCIENCES, INC.

### Notes to Financial Statements (unaudited), Continued

#### 1. Summary of Significant Accounting Policies, Continued:

**Income Tax Uncertainties, Continued:** Management evaluated the Company's tax positions and concluded that the Company has taken no uncertain tax positions that require adjustment to the financial statements to comply with the provisions of this guidance. The Company is not currently under audit by any tax jurisdiction.

**Start-up and Organizational Expenses:** The Company expenses start-up and organizational expenses as incurred. Total start-up and organizational expenses were $2,566 and $150 for 2021 and 2020, respectively.

**Stock-Based Compensation:** The Company follows FASB guidance, related to stock-based payments, which requires that stock-based compensation transactions be accounted for using a fair-value based method and recognized as expense in the statements of operations. Stock-based compensation is recognized and amortized to compensation expense over the applicable service or vesting period.

#### 2. Advances - Stockholder:

During 2021 and 2020, a stockholder of the Company advanced funds to the Company to assist with working capital obligations. The advances do not bear interest and are to be repaid upon the Company having sufficient cash flow to make payments. The outstanding balance on the advances was $3,729 and $150 at December 31, 2021 and 2020, respectively.

#### 3. Stockholders' Deficit:

Pursuant to the Company's amended articles of incorporation, the Company is authorized to issue 20,000,000 shares of common stock at $0.001 par value per share and 2,000 shares of preferred stock at $0.001 par value per share as of December 31, 2021. As of December 31, 2020, the Company was authorized to issue 10,000,000 shares of common stock at $0.001 par value per share and 2,000 shares of preferred stock at $0.001 par value per share. The Company had 10,000,000 and 9,850,000 shares of common stock issued and outstanding at December 31, 2021 and 2020, respectively. The Company had 2,000 shares of preferred stock issued and outstanding at December 31, 2021 and 2020. The holder of each share of common stock is entitled to one vote per share and the holder of each share of preferred stock is entitled to 5,000 votes per share. The voting, dividend, and liquidation rights of the holders of the common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock.

The Company issued the shares during 2021 and 2020 for services rendered to the Company and as a form of stock based compensation. Management determined the fair value of the stock issued to be its par value, $0.001 per share. Stock compensation of $150 and $9,852 was recognized for 2021 and 2020, respectively.

7

## ADDICTION CURE THERAPEUTIC SCIENCES, INC.

### Notes to Financial Statements (unaudited), Continued

#### 4. Income Taxes:

The Company has federal and state net operating loss carry forwards of approximately $12,700 at December 31, 2021, available to offset future taxable income in accordance with the Internal Revenue Service regulations.

Management believes that a full valuation allowance is appropriate given the current estimates of future taxable income, as well as consideration of available tax planning strategies. The ultimate realization of the net deferred tax asset is dependent upon the generation of future taxable income during periods in which temporary differences become deductible.

#### 5. Subsequent Events: Management has evaluated subsequent events through August 17, 2022 the date the financial statements were available to be issued, and has determined that other than disclosed below, there are no additional subsequent events to be reported in the accompanying financial statements.

During 2022, the Company issued 2,100,000 shares of common stock for a total of $12,500 and for services rendered to the Company.

During 2022, the Company issued 1,205,000 stock options to various advisors of the Company. The options expire in June 2027.

8

**Attachment 3:** `certificateofincorporation.pdf`

6/16/22
Amew
A. Page, J. Hay

![img-0.jpeg](img-0.jpeg)

# FLORIDA DEPARTMENT OF STATE
DIVISION OF CORPORATIONS

Attached is a form for filing Articles of Amendment to amend the articles of incorporation of a Florida Profit Corporation pursuant to section 607.1006, Florida Statutes. This is a basic amendment form and may not satisfy all statutory requirements for amending.

A corporation can amend or add as many articles as necessary in one amendment.

The original incorporators cannot be amended.
If amending the name of the corporation, the new name must be distinguishable on the records of the Florida Department of State. A preliminary search for name availability can be made through the Division's website at www.sunbiz.org. You are responsible for any name infringement that may result from your corporate name selection.
If amending the registered agent, the new agent must sign accepting the appointment and state that he/she is familiar with the obligations of the position.
If amending/adding officers/directors, list titles and addresses for each officer/director.
If amending from a general corporation to a professional corporation, the purpose (specific nature of business) must be amended or added if not contained in the articles of incorporation.

If a section is not being amended, enter N/A or Not Applicable.

The document must be typed or printed and must be legible.

Pursuant to section 607.0123, Florida Statutes, a delayed effective date may be specified but may not be later than the 90th day after the date on which the document is filed.

Filing Fee $35.00 (Includes a letter of acknowledgment)

Certified Copy (optional) $8.75

Certificate of Status (optional) $8.75

Send one check in the total amount made payable to the Florida Department of State.

Please include a letter containing your telephone number, return address and certification requirements, or complete the attached cover letter.

Mailing Address

Amendment Section

Division of Corporations

P.O. Box 6327

Tallahassee, FL 32314

Street Address

Amendment Section

Division of Corporations

The Centre of Tallahassee

2415 N. Monroe Street, Suite 810

Tallahassee, FL 32303

For further information you may call the Amendment Section at (850) 245-6050

CR2E011 (1/20)

# COVER LETTER

TO: Amendment Section

Division of Corporations

NAME OF CORPORATION: Addiction Cure Therapeutic Sciences Inc

DOCUMENT NUMBER: P20000032521

The enclosed Articles of Amendment and fee are submitted for filing.

Please return all correspondence concerning this matter to the following:

Jack Levine

Name of Contact Person

Addiction Cure Therapeutic Sciences Inc

Firm/ Company

6574 North State Road 7, #277

Address

Coconut Creek, FL. 33073

City/ State and Zip Code

Parklandjack1@aol.com

E-mail address: (to be used for future annual report notification)

For further information concerning this matter, please call:

Jack Levine

Name of Contact Person

at (954) 732-9122

Area Code & Daytime Telephone Number

Enclosed is a check for the following amount made payable to the Florida Department of State:

☑ $35 Filing Fee

☐ $43.75 Filing Fee &

Certificate of Status

☐ $43.75 Filing Fee &

Certified Copy

(Additional copy is enclosed)

☐ $52.50 Filing Fee

Certificate of Status

Certified Copy

(Additional Copy is enclosed)

Mailing Address

Amendment Section

Division of Corporations

P.O. Box 6327

Tallahassee, FL 32314

Street Address

Amendment Section

Division of Corporations

The Centre of Tallahassee

2415 N. Monroe Street, Suite 810

Tallahassee, FL 32303

# Articles of Amendment

to

# Articles of Incorporation

of

Addiction Cure Therapeutic Sciences Inc

(Name of Corporation as currently filed with the Florida Dept. of State)

P20000032521

(Document Number of Corporation (if known)

Pursuant to the provisions of section 607.1006, Florida Statutes, this Florida Profit Corporation adopts the following amendment(s) to its Articles of Incorporation:

A. If amending name, enter the new name of the corporation:

The new name must be distinguishable and contain the word "corporation," "company," or "incorporated" or the abbreviation "Corp.," "Inc.," or Co.," or the designation "Corp," "Inc," or "Co". A professional corporation name must contain the word "chartered," "professional association," or the abbreviation "P.A."

B. Enter new principal office address, if applicable:

(Principal office address MUST BE A STREET ADDRESS)

C. Enter new mailing address, if applicable:

(Mailing address MAY BE A POST OFFICE BOX)

D. If amending the registered agent and/or registered office address in Florida, enter the name of the new registered agent and/or the new registered office address:

Name of New Registered Agent

(Florida street address)

New Registered Office Address: , Florida

(City) (Zip Code)

New Registered Agent's Signature, if changing Registered Agent:

I hereby accept the appointment as registered agent. I am familiar with and accept the obligations of the position.

Signature of New Registered Agent, if changing

Check if applicable

☐ The amendment(s) is/are being filed pursuant to s. 607.0120 (11) (e), F.S.

If amending the Officers and/or Directors, enter the title and name of each officer/director being removed and title, name, and address of each Officer and/or Director being added:

(Attach additional sheets, if necessary)

Please note the officer/director title by the first letter of the office title:

P = President; V = Vice President; T = Treasurer; S = Secretary; D = Director; TR = Trustee; C = Chairman or Clerk; CEO = Chief Executive Officer; CFO = Chief Financial Officer. If an officer/director holds more than one title, list the first letter of each office held. President, Treasurer, Director would be PTD.

Changes should be noted in the following manner. Currently John Doe is listed as the PST and Mike Jones is listed as the V. There is a change, Mike Jones leaves the corporation, Sally Smith is named the V and S. These should be noted as John Doe, PT as a Change, Mike Jones, V as Remove, and Sally Smith, SV as an Add.

Example:

| ☑ Change | PT | John Doe |  |
| --- | --- | --- | --- |
| ☑ Remove | V | Mike Jones |  |
| ☑ Add | SV | Sally Smith |  |
| Type of Action (Check One) | Title | Name | Address |
| 1) ☐ Change |  |  |  |
| ☐ Add |  |  |  |
| ☐ Remove |  |  |  |
| 2) ☐ Change |  |  |  |
| ☐ Add |  |  |  |
| ☐ Remove |  |  |  |
| 3) ☐ Change |  |  |  |
| ☐ Add |  |  |  |
| ☐ Remove |  |  |  |
| 4) ☐ Change |  |  |  |
| ☐ Add |  |  |  |
| ☐ Remove |  |  |  |
| 5) ☐ Change |  |  |  |
| ☐ Add |  |  |  |
| ☐ Remove |  |  |  |
| 6) ☐ Change |  |  |  |
| ☐ Add |  |  |  |
| ☐ Remove |  |  |  |

E. If amending or adding additional Articles, enter change(s) here:

(Attach additional sheets, if necessary). (Be specific)

ARTICLE IV Item (a) "Authorized Shares" is replaced in its entirety by the following: ARTICLE IV (a) Authorized Shares.
The aggregate number of shares which the corporation shall have the authority to issue is 20,002,000 (Twenty Million Two Thousand Shares) shares. 20,000,000 (Twenty million) shares shall be designated as common stock and shall have a par value of $0.001. 2000 (Two Thousand) shares shall be designated as preferred stock and shall have a par value of $0.001 per share and shall be issued for such consideration as expressed in dollars as the Board of Directors may from time to time determine.

F. If an amendment provides for an exchange, reclassification, or cancellation of issued shares, provisions for implementing the amendment if not contained in the amendment itself:

(if not applicable, indicate N/A)

date this document was signed.

Effective date if applicable: June 16, 2022

(no more than 90 days after amendment file date)

Note: If the date inserted in this block does not meet the applicable statutory filing requirements, this date will not be listed as the document's effective date on the Department of State's records.

Adoption of Amendment(s)

(CHECK ONE)

The amendment(s) was/were adopted by the incorporators, or board of directors without shareholder action and shareholder action was not required.
The amendment(s) was/were adopted by the shareholders. The number of votes cast for the amendment(s) by the shareholders was/were sufficient for approval.
The amendment(s) was/were approved by the shareholders through voting groups. The following statement must be separately provided for each voting group entitled to vote separately on the amendment(s):

"The number of votes cast for the amendment(s) was/were sufficient for approval

by

(voting group)

June 16, 2022

Dated

Signature

(By a director, president or other officer - if directors or officers have not been selected, by an incorporator - if in the hands of a receiver, trustee, or other court appointed fiduciary by that fiduciary)

Jack Levine

(Typed or printed name of person signing)

President

(Title of person signing)

# COVER LETTER

TO: Amendment Section

Division of Corporations

NAME OF CORPORATION: ADDICTION CURE THERAPEUTIC SCIENCES INC

DOCUMENT NUMBER: P20000032521

The enclosed Articles of Amendment and fee are submitted for filing.

Please return all correspondence concerning this matter to the following:

Jack Levine

Name of Contact Person

c/o Addiction Cure Therapeutic Sciences Inc

Firm/ Company

6574 NORTH STATE ROAD 7, SUITE 277

Address

Coconut Creek, FL.33073

City/ State and Zip Code

Parklandjack1@aol.com

E-mail address: (to be used for future annual report notification)

For further information concerning this matter, please call:

Jack Levine

954 732-9122

Name of Contact Person

Area Code & Daytime Telephone Number

Enclosed is a check for the following amount made payable to the Florida Department of State:

☑ $35 Filing Fee

☐ $43.75 Filing Fee &

Certificate of Status

☐ $43.75 Filing Fee &

Certified Copy

(Additional copy is enclosed)

☐ $52.50 Filing Fee

Certificate of Status

Certified Copy

(Additional Copy is enclosed)

Mailing Address

Amendment Section

Division of Corporations

P.O. Box 6327

Tallahassee, FL 32314

Street Address

Amendment Section

Division of Corporations

The Centre of Tallahassee

2415 N. Monroe Street, Suite 810

Tallahassee, FL 32303

Articles of Amendment

to

Articles of Incorporation

of

FILED

(Name of Corporation as currently filed with the Florida Trade and State)

ADDICTION CURE THERAPEUTIC SCIENCES INC

SECRETARY OF STATE

(Document Number of Corporation (if known) TALLAHASSEE, FL

Pursuant to the provisions of section 607.1006, Florida Statutes, this Florida Profit Corporation adopts the following amendment(s) to its Articles of Incorporation:

A. If amending name, enter the new name of the corporation:

The new

name must be distinguishable and contain the word "corporation," "company," or "incorporated" or the abbreviation "Corp."

"Inc.," or Co.," or the designation "Corp." "Inc." or "Co". A professional corporation name must contain the word

"chartered," "professional association," or the abbreviation "P.A."

B. Enter new principal office address, if applicable:

(Principal office address MUST BE A STREET ADDRESS)

C. Enter new mailing address, if applicable:

(Mailing address MAY BE A POST OFFICE BOX)

D. If amending the registered agent and/or registered office address in Florida, enter the name of the new registered agent and/or the new registered office address:

Name of New Registered Agent

(Florida street address)

New Registered Office Address:

Florida

(City)

(Zip Code)

New Registered Agent's Signature, if changing Registered Agent:

I hereby accept the appointment as registered agent. I am familiar with and accept the obligations of the position.

Signature of New Registered Agent, if changing

Check if applicable

☐ The amendment(s) is/are being filed pursuant to s. 607.0120 (11) (c), F.S.

If amending the Officers and/or Directors, enter the title and name of each officer/director being removed and title, name, and address of each Officer and/or Director being added:

(Attach additional sheets, if necessary)

Please note the officer/director title by the first letter of the office title:

P = President; V = Vice President; T = Treasurer; S = Secretary; D = Director; TR = Trustee; C = Chairman or Clerk; CEO = Chief Executive Officer; CFO = Chief Financial Officer. If an officer/director holds more than one title, list the first letter of each office held. President, Treasurer, Director would be PTD.

Changes should be noted in the following manner. Currently John Doe is listed as the PST and Mike Jones is listed as the V. There is a change, Mike Jones leaves the corporation, Sally Smith is named the V and S. These should be noted as John Doe, PT as a Change, Mike Jones, V as Remove, and Sally Smith, SV as an Add.

Example:

| ☑ Change | PT | John Doe |  |
| --- | --- | --- | --- |
| ☑ Remove | V | Mike Jones |  |
| ☑ Add | SV | Sally Smith |  |
| Type of Action (Check One) | Title | Name | Address |
| 1) ☐ Change | S | Jack Levine | 6574 North State Road 7, Suite 277 |
| ☑ Add |  |  | Coconut Creek, FL 30073 |
| ☐ Remove |  |  |  |
| 2) ☐ Change | V | Michael Lambert | 625 NE 7th Ave |
| ☑ Add |  |  | Delray Beach, FL 33483 |
| ☐ Remove |  |  |  |
| 3) ☐ Change |  |  |  |
| ☐ Add |  |  |  |
| ☐ Remove |  |  |  |
| 4) ☐ Change |  |  |  |
| ☐ Add |  |  |  |
| ☐ Remove |  |  |  |
| 5) ☐ Change |  |  |  |
| ☐ Add |  |  |  |
| ☐ Remove |  |  |  |
| 6) ☐ Change |  |  |  |
| ☐ Add |  |  |  |
| ☐ Remove |  |  |  |

E. If amending or adding additional Articles, enter change(s) here:

(Attach additional sheets, if necessary). (Be specific)

SEE ATTACHED PAPER

F. If an amendment provides for an exchange, reclassification, or cancellation of issued shares, provisions for implementing the amendment if not contained in the amendment itself:
(if not applicable, indicate N/A)

N/A

The date of each amendment(s) adoption: _________________________, if other than the date this document was signed.

Effective date if applicable: _________________________
(no more than 90 days after amendment file date)

Note: If the date inserted in this block does not meet the applicable statutory filing requirements, this date will not be listed as the document's effective date on the Department of State's records.

Adoption of Amendment(s) (CHECK ONE)

☑ The amendment(s) was/were adopted by the incorporators, or board of directors without shareholder action and shareholder action was not required.
☐ The amendment(s) was/were adopted by the shareholders. The number of votes cast for the amendment(s) by the shareholders was/were sufficient for approval.
☐ The amendment(s) was/were approved by the shareholders through voting groups. The following statement must be separately provided for each voting group entitled to vote separately on the amendment(s):

"The number of votes cast for the amendment(s) was/were sufficient for approval

by _________________________"

(voting group)

June 1, 2021

Dated _________________________

Signature

(By a director, president or other officer - if directors or officers have not been selected, by an incorporator - if in the hands of a receiver, trustee, or other court appointed fiduciary by that fiduciary)

Jack Levine

_________________________
(Typed or printed name of person signing)

President

_________________________
(Title of person signing)

ITEM E: Original version of Article IV is hereby deleted in its entirety and replaced by the following:

# ARTICLE IV

(a) Authorized Shares. The aggregate number of shares which the corporation shall have the authority to issue is 10,002,000 (Ten Million Two Thousand) shares. 10,000,000 (Ten Million) shall be designated "Common Stock" and shall have a par value of $0.001. (Two Thousand) 2,000 shares shall be designated as "Preferred Stock" and shall have a par value of $0.001 per share and shall be issued for such consideration expressed in dollars as the Board of Directors may from time to time determine.
(b) Consideration for Shares. All shares of Common Stock and Preferred Stock shall be issued by the Corporation for cash, property or services actually performed, for no less than the par value of $0.001 for Common Stock and $0.001 for Preferred Stock all shares shall be fully paid and nonassessable.
(c) Issuance of Preferred Stock. The Preferred Stock authorized by the certificate of incorporation may be issued from time to time in series. The Board of Directors of the Corporation is authorized to establish such series, to fix and determine the variations in the relative rights and preferences as between series and to thereafter issue such stock from time to time. The Board of Directors is also authorized to allow for conversion of the Preferred Stock to Common Stock under terms and conditions as determined by the Board of Directors
(d) Dividends. Dividends in cash, property or share of the Corporation may be paid upon the Common and Preferred Stock, as and when declared by the Board of Directors, out of funds of the corporation to the extent and in the manner permitted by law.
(e) Voting Rights & Cumulative Voting. Each outstanding share of Common Stock shall be entitled to one vote, and each fractional share of Common Stock shall be entitled to a corresponding fractional vote on each matter submitted to a vote of shareholders. The voting rights of Preferred Stock shall be entitled to 5,000 (five thousand) votes per each share. Cumulative voting shall not be allowed in the election of directors of the corporation.

# P10000032621

![img-0.jpeg](img-0.jpeg)

(Requestor's Name)

(Address)

(Address)

(City/State/Zip/Phone #)

☐

PICK-UP

☐

WAIT

☐

MAIL

(Business Entity Name)

(Document Number)

Certified Copies

Certificates of Status

Special Instructions to Filing Officer:

Office Use Only

000367430370

06/04/21--01012--003 **35.00

2021 JUN -4 AM 7:35
SECRETARY OF STATE
TALLAHASSEE, FL

FILED

Anissa Butler

7-9-21

# Electronic Articles of Incorporation For

P20000032521  
FILED  
April 28, 2020  
Sec. Of State  
wlawrence

ADDICTION CURE THERAPEUTIC SCIENCES INC

The undersigned incorporator, for the purpose of forming a Florida profit corporation, hereby adopts the following Articles of Incorporation:

## Article I

The name of the corporation is:

ADDICTION CURE THERAPEUTIC SCIENCES INC

## Article II

The principal place of business address:

6574 NORTH STATE ROAD 7  
SUITE # 277  
COCONUT CREEK, FL. 33073

The mailing address of the corporation is:

6574 NORTH STATE ROAD 7,  
SUITE # 277  
COCONUT CREEK, FL. 33073

## Article III

The purpose for which this corporation is organized is:

ANY AND ALL LAWFUL BUSINESS.

## Article IV

The number of shares the corporation is authorized to issue is:

1,000,000

## Article V

The name and Florida street address of the registered agent is:

JACK LEVINE  
6574 NORTH STATE ROAD 7  
SUITE # 277  
COCONUT CREEK, FL. 33073

I certify that I am familiar with and accept the responsibilities of registered agent.

Registered Agent Signature: JACK LEVINE

# Article VI

The name and address of the incorporator is:

JACK LEVINE

6574 NORTH STATE ROAD 7

SUITE #277

COCONUT CREEK

P20000032521

FILED

April 28, 2020

Sec. Of State

wlawrence

Electronic Signature of Incorporator: JACK LEVINE

I am the incorporator submitting these Articles of Incorporation and affirm that the facts stated herein are true. I am aware that false information submitted in a document to the Department of State constitutes a third degree felony as provided for in s.817.155, F.S. I understand the requirement to file an annual report between January 1st and May 1st in the calendar year following formation of this corporation and every year thereafter to maintain "active" status.

# Article VII

The initial officer(s) and/or director(s) of the corporation is/are:

Title: P

JACK LEVINE

6574 NORTH STATE ROAD 7, #277

COCONUT CREEK, FL. 33073

# Article VIII

The effective date for this corporation shall be:

04/28/2020

**Attachment 4:** `corporatebylaws.pdf`

# **Bylaws of**
**Addiction Cure Therapeutic Sciences Inc.**

**I. INCORPORATION.** It is recognized that Addiction Cure Therapeutic Sciences Inc. (the “Corporation”) is a duly organized corporation authorized to do business in the state of Florida by its articles of incorporation or similar registered documents and under state statutes.

**II. ANNUAL MEETING.** Meetings of shareholders shall be held at the principal office of the corporation or at such other place as may be determined from time to time by the Board of Directors of the Corporation. The purpose of the annual meeting shall be to elect the Board of Directors, officers, and to decide other business activities and decisions.

An annual meeting must be held within 13 months after its last meeting or organization. If an annual meeting has not been made in such time, then any shareholder holding more than five percent (5) of the Corporation’s voting shares, or any director, may demand a meeting to be held within 30 days after notice has been made.

**III. SPECIAL MEETINGS.** Unless otherwise prescribed by statute, special meetings of the shareholders, may be called only by:

The President or Chief Executive Officer of the Corporation;
A majority of the Board of Directors of the Corporation; or
A majority of the Corporation’s shareholders holding voting shares.

After a special meeting has been called, the Board of Directors shall decide it’s time and place within five days after the demand therefore has been made.

**IV. PLACE OF MEETINGS:** The venue of all annual and special meetings of the Corporation shall be determined by the Board of Directors. By default, such meeting shall take place at the principal office of the corporation. Shareholders of all classes and series may attend any meeting of the Corporation.

Such meetings may be attended:

- In person at the Corporation’s principal office, or
- By remote communication (i.e., phone, web, etc.)

All communication methods shall offer each attending voting shareholder the right to be present, vote on business matters, and offer his or her consent or dissent for any actionable item.

**V. DISSOLUTION:** The Corporation may only be dissolved only in the following ways:

Majority vote of the Board of Directors

Majority vote of the voting shareholders

**VI. NOTICE OF MEETINGS.** Written notice shall be provided to each shareholder of any meeting that such shareholder is permitted to take action in the form of a vote and/or offer their consent or dissent for any actionable item. Such written notice shall detail the time, place, remote access (if available) and in the case of a special meeting, the purpose or purposes for which the meeting is called. Unless otherwise provided by law, written notice of any meeting shall be given not less than 10 days and no more than 60 days before the date of the meeting. Notice of any meeting can be sent to the last known contact information of such shareholder as reflected on the records of the Corporation by:

- Email;
- U.S.P.S. Mail;
- Fax; or
- Hand-delivery

**VII: QUORUM:** a quorum, which represents the required number of individuals to be present to hold an annual or special meeting, shall be:

- 51% of the board of the directors' present
- 51% of the voting shareholders present

Upon meeting requirements of the quorum, the attending individuals of the meeting shall be able to take action and make decisions for the Corporation.

**VIII: ACTIONS OF THE CORPORATION:** Actions made on behalf of the Corporation may be made only as follows:

Any action required to be taken, or which may be taken, at any meeting, whether annual or special, may be taking only at such meeting, and only in accordance with these bylaws.

Any action required be taken or which may be taken at any meeting, whether annual or special, may be taken without a meeting, without prior notice, and without a vote, if consent in writing, setting forth the action so taken, is signed by the holders of outstanding voting shares having not less than the minimum number of votes that would be necessary to take such action at a meeting at which all shareholders entitled to vote were present and voted.

**IX. CORPORATE SEAL.** The Corporation shall have a corporate seal. The corporate seal shall be in such a form that the Board of Directors shall approve.

**X. EXECUTION OF DOCUMENTS.** All contracts, checks, drafts, demands for money, notes and other legal instruments or rights of any nature of the Corporation may be signed by:

President/CEO
Treasurer

**XI. INDEMNIFICATION:** Subject to any applicable statute, rule or regulation, all directors and officers of the corporation shall be indemnified and held harmless by the corporation to the fullest extent of the law. This includes, but is not limited to, a party to any action, suit, or proceeding, by reason of the fact of being an officer or director, or was a director, officer, agent or employee of the Corporation during the time that the conduct at issue was engaged in. The Corporation shall provide reasonable expenses, including attorney's fees, actually and necessarily incurred in connection with such action, suit, or proceeding. Notwithstanding the foregoing, no indemnification shall be made by the Corporation of judgment or other final determination if the acts are determined by a Court of competent jurisdiction to have been committed in bad faith or the result of active or deliberate fraud or dishonesty or clear and gross negligence.

**XII. AMENDMENTS.** These bylaws may be amended by:

-Majority vote of the Board of Directors
-Majority vote of the voting shareholders

**XIII. CLASSES OF STOCK.** The Board of Directors of the Corporation may issue stock in the following classes:

-Common shares which have one vote per share of each stock
-Preferred shares which shall have 5000 votes for each share of stock
-Nonvoting shares

**XIV. STOCK CERTIFICATES.** The Corporation may provide shares of stock without certificates. The Corporation, within a reasonable time after issue or transfer of shares without certificates, will provide shareholders a written statement of the information that is required by law to be on the certificates.

Certificates for Shares. The Board of Directors shall determine whether shares of the corporation shall be uncertificated or certificated. If certificated shares are issued, certificates representing shares in the corporation shall be signed (either manually or by facsimile) by the Corporation's president or vice president and the secretary or an assistant secretary and may be sealed with the seal of the corporation or a facsimile thereof. A certificate that has been signed by an officer or officers who thereafter cease to hold such office shall be and remain valid.

Transfer of Shares; Ownership of Shares. Transfers of shares of stock of the Corporation shall be made only on the stock transfer books of the corporation, and only after the surrender to the Corporation of the certificates representing such shares. Except as provided by F.S.

607.0721, the person in whose name shares stand on the books of the Corporation shall be deemed by the Corporation to be the owner thereof for all purposes, and the Corporation shall not be bound to recognize any equitable or other claim to, or interest in, such shares on the part of any other person, whether or not it shall have express or other notice thereof.

Loss or Destruction of Certificates. In case of loss or destruction of any certificate of shares, another may be issued in its place upon proof of such loss or destruction and upon the giving of a satisfactory bond of indemnity to the Corporation. A new certificate may be issued without requiring any bond, when, in the sole judgment of the Board of Directors, it is proper to do so.

a.) Voting Per Share. Except as otherwise provided in the articles of incorporation or by F.S. 607.0721, each common stock voting shareholder is entitled to one vote for each outstanding share held by him or her on each matter voted at a shareholders' meeting. Each preferred stock share shall be entitled to 5000 votes per share. Any non-voting shares may attend any meeting of the Corporation but shall not be entitled to vote thereat.

b.) Voting of Shares. Voting shares standing in the name of another corporation, domestic or foreign, may be voted by the officer, agent, or proxy designated by the bylaws of the corporate shareholder or, in the absence of any applicable bylaw, by a person or persons designated by the board of directors of the corporate shareholder in writing to the Corporation. In the absence of any such designation or, in case of conflicting designation by the corporate shareholder, the Chairperson of the Corporation's Board of Directors, the President, any Vice-president, the Secretary, and the Treasurer of the corporate shareholder, in that order, shall be presumed to be fully authorized to vote the shares.

Shares held by an administrator, executor, guardian, personal representative, or conservator may be voted by him or her, either in person or by proxy, without a transfer of such shares into his or her name. Shares standing in the name of a trustee may be voted by the trustee, either in person or by proxy, but no trustee shall be entitled to vote shares held by him or her without a transfer of such shares into his or her name or the name of his or her nominee.

Shares held by, or under the control of, a receiver, a trustee in bankruptcy proceedings, or an assignee for the benefit of creditors may be voted by such person without the transfer into his or her name.

**XV. DIRECTORS.** The Corporation shall be managed by the Board of Directors consisting of three Directors, or such other number as any existing members of the Board of Directors may direct.

a.) Nomination. The Board of Directors shall be elected by the voting shareholders at the annual meeting of the Corporation by the vote of such shareholders holding of record in the aggregate at least a plurality of the shares of stock of the Corporation present in person or by proxy and entitled to vote at the annual meeting of shareholders. Each Director shall serve a

term of three years unless earlier removed by the shareholders or upon the Director’s resignation.

b.) Quorum. A majority of the Board of Directors must be in attendance (in person or by any other means permitted by these bylaws) at any meeting in order for a quorum to exist. No action may be taken by the Board of Directors unless such quorum exists.

c.) Regular meetings. By resolution and after the annual meeting, the Board of Directors may provide a time and place to meet without notice other than that resolution.

d.) Remote communication. One or more Directors may participate in the meetings of the board or committee of the board by any communication, including telephonically or by videoconference, by means of which all participating Directors can simultaneously hear each other during the meeting. Participation in this manner shall constitute presence in person at such a meeting.

e.) Conflict of interest. If any director who has a conflict of interest regarding any vote, either during a regular or special meeting, or with respect any other corporate action otherwise taken, such conflict of interest shall not invalidate such vote or action.

f.) Board of Directors actions. The act of a majority of directors present at any meeting at which a quorum is present shall be the act of the Board of Directors, except as provided by law, the articles of incorporation, or these bylaws. Each director present shall have one vote, irrespective of the number of shares of stock, if any, he or she may hold.

g.) Presumption of Assent. A Director of the Corporation who is present at a meeting of the Board of Directors at which action on any corporate matter is taken shall be presumed to have assented to the action taken unless his or her dissent shall be entered in the minutes of the meeting or unless he or she shall file his or her written dissent to such action with the person acting as the Secretary of the meeting before the adjournment thereof or shall forward such dissent by priority mail to the Secretary of the Corporation immediately after the adjournment of the meeting. Such right to dissent shall not apply to a Director who voted in favor of such action.

h.) Removal. Any director or the entire Board of Directors may be removed, at any time, with or without cause, by the holders of a majority of the voting shareholders attending a meeting for such purpose.

i.) Vacancies except as otherwise provided by law. Any vacancy in the Board of Directors of the Corporation occurring by reason of an increase in the authorized number of Directors or by reason of the death, withdrawal, removal, disqualification, inability to act, or resignation of a Director shall be filed by the majority of Directors then in office. The successor Director shall serve the unexpired portion of the term of his or her predecessor. Any Director may resign at any time by giving written notice to the Board of Directors or the Secretary of the Corporation.

j.) Committees. The Board of Directors, by resolution, may create one or more committees, each consisting of one or more Directors or other appointed members. Each such committee shall serve at the pleasure of the Board of Directors. All provisions under any applicable statute and/or these bylaws related to meetings, action without meetings, notice, and waiver of notice, quorum and voting requirements of the Board of Directors shall apply to such committees and their members.

k.) Consent in lieu of meetings. Any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting of all the members of the Board of Directors or committee, as the case may be, by consent thereto in writing, such writing or writings to be filed with the minutes of proceedings of the Board or committee.

l.) Compensation. The Board of Directors shall have the authority to fix the compensation of Directors. A fixed sum and expenses of attendance may be allowed for attendance at each regular or special meeting of the Board of Directors including their services as members of committees of the Board of Directors.

**XVI. OFFICERS.** The officers of the Corporation shall be a Chairperson, a President, a Secretary, and a Treasurer, and such other officers as the Board of Directors may from time to time appoint, including one or more vice-presidents and such other officers as it deems advisable. Each such officer shall exercise such powers and perform such duties as shall be set forth herein and such other powers and duties as may be specified from time to time by the Board of Directors. The officers of the corporation shall be elected by the Board of Directors. Each of the Chairperson, President, and/or any Vice-President shall have only the following powers unless other powers are specifically delegated to him or her in writing by the Board of Directors.

a.) Chairperson. The chairperson shall have overall responsibility and authority for management and operations of the Corporation and shall preside at all meetings of the Board of Directors and Shareholders and shall ensure that all orders and resolutions of the Board of Directors and shareholders are implemented.

b.) President/CEO. The President/CEO shall be the chief operating officer of the corporation and shall have full responsibility and authority for management of the day-to-day operations of the Corporation. The President shall be an ex-officio member of all committees and shall have the general powers and duties management supervision usually vested in the office of president of a corporation.

c.) Treasurer. The Treasurer shall be the chief financial officer of the Corporation and shall have responsibility for the custody of the corporate funds and securities, to keep full and accurate records and accounts of receipts and disbursements in books belonging to the Corporation and shall keep the monies of the Corporation in a separate account in the name of the Corporation. The Treasurer shall provide to the President and the Board of Directors, at the regular meetings of the Board of Directors, or whenever requested by the Board of

Directors, an account of all financial transactions and of the financial condition of the Corporation.

d.) Secretary. The secretary shall attend all meetings of the Board of Directors, and committees of the Board of Directors, and any meetings of the shareholders of the Corporation, and shall prepare and maintain written minutes of votes, resolutions and actions taken at any such meeting, and shall record the same in books and records to be kept for those purposes. The secretary shall give, or cause to be given, a notice of all meetings of the shareholders and special meetings of the Board of Directors and shall perform other duties as may be prescribed by the Board of Directors or President of the Corporation and under whose supervision the Secretary shall be. The Secretary shall maintain the records, minutes and non-financial corporate books of the Corporation and may attest any instruments signed by any officer of the Corporation.

**XVII. LIST OF SHAREHOLDERS.** The officer of the Corporation who has charge of the stock ledger of the Corporation shall prepare and make, at least 10 days before any meeting of shareholders, a complete list of the shareholders entitled to vote at the meeting, arranged alphabetically, and showing the last known address of each shareholder and the number of shares held by each shareholder. The list shall be open to the examination of any shareholder for any purpose germane to the meeting, during ordinary business hours, for a period of at least 10 days before the meeting, either at a mutually agreeable location or where the meeting is to be held. The list shall also be produced and kept available at the time and place of the meeting, for the entire duration of the meeting, and may be inspected by any shareholder present at the meeting.

**XVIII. AMENDMENTS TO BYLAWS.** A majority of the members of the Board of Directors of the Corporation may, from time-to-time, amend these bylaws in such manner as the Board of Directors may deem appropriate.

**IX. PRIORITY OF LAW, RULE OR REGULATION.** In the event that any provision of these bylaws is in conflict with, or violative of, any law, rule or regulation applicable to the Corporation or its business operations, such provision shall be deemed to be amended to comply with such law, rule or regulation, or if such amendment is not possible or practicable, such provision is deemed to be stricken from these bylaws and of no legal force or effect.

**CERTIFICATION.** By their signatures below, the undersigned hereby certify the foregoing bylaws to be a true and correct copy of the bylaws of the Corporation, duly adopted by the initial Board of Directors of the Corporation on May 1, 2020.

_________________________
Jack Levine, President/CEO

Date _________________

_________________________
Michael Lambert, Vice President

Date _________________

**Attachment 5:** `otherfinancial.pdf`

# Record Ownership and Voting Agreement

This Record Ownership and Voting Agreement (this “Agreement”) is entered into as of the date of electronic consent by the parties using the website www.netcapital.com (the “Portal”), by and among NetCapital Funding Portal Inc., a Delaware corporation (“NetCapital”), MG Teixeira Inc, a Connecticut corporation (the “Record Owner”), and the undersigned investor (“Investor”).

The Record Owner has agreed to open and maintain the Account (as defined below) for Investor and to provide other services to Investor in connection with the Account. This Agreement sets out, among other things, the terms under which the Record Owner will provide those services to Investor and the arrangements that will apply in connection with those services.

In consideration of the mutual promises herein made and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:

## 1. Interpretation

### 1.1 Definitions

In this Agreement:

- • “Account” means the account opened by the Record Owner and consisting of the beneficial interests in any Shares that were offered for sale by the Issuer on the Portal and purchased by Investor.
- • “Account Balance” means, in relation to the Account, the number of Shares of each Issuer beneficially owned by Investor, including all of Investor’s rights to and interest in the balance from time to time on that Account.
- • “Business Day” means a weekday that is not a federal holiday.
- • “Escrow Agent” means Boston Private Bank and Trust Company.
- • “Fees” means the fees and charges referred to in clause 5.1 of this Agreement.
- • “Issuer” means each issuer of the Shares.
- • “Shares” means the beneficial interests in the uncertificated shares of common stock or preferred stock or the units of convertible debt, limited liability company membership interests or limited partnership interests that were beneficially purchased by Investor on the Portal.
- • “Termination Date” means the date on which this Agreement is terminated by the Record Owner or by Investor as permitted hereunder.
- • “Transfer Agent” means Equity Stock Transfer LLC, or a successor transfer agent.
- • “Withdrawal Date” means the date referred to in clause 2.2 of this Agreement.

### 1.2. Headings

The headings in this Agreement do not affect its interpretation.

### 1.3. Singular and plural

References to the singular include the plural and vice versa.

## 2. Account

### 2.1. Opening Account

The Record Owner shall open and maintain the Account for the beneficial interests in the Shares beneficially held by Investor.

### 2.2. Deposits and withdrawals

The balance of Investor's Account shall reflect the Shares beneficially held by Investor. A deposit of Shares is made into Investor's Account when the Escrow Agent sends payment funds to the Issuer or a seller of Shares, as the case may be, and the Record Owner receives a record from the Transfer Agent of the number of Shares that Investor beneficially holds. A withdrawal occurs when the Record Owner receives notice from the Transfer Agent that the Shares have been beneficially sold or transferred.

### 2.3. Reports

Reports relating to deposits into and withdrawals from the Account and the Account Balance will be available to Investor daily by means of a section on the Portal to which Investor may log in.

## 3. Services of the Record Owner

### 3.1. General

Investor and the Record Owner understand and agree that the Record Owner will be the legal but not the beneficial owner of the Shares.

### 3.2. Ownership of Securities

The Record Owner will be the sole holder of legal title to the Shares while Investor will hold beneficial ownership of the Shares. The Record Owner will be the sole record holder of the Shares on the books and records of the Issuer. The sole dispositive record of Investor's beneficial ownership of the Shares will be in the books and records of the Transfer Agent. Investor shall be entitled to all proceeds of the sale of Shares, net of fees and commissions.

### 3.3. Voting of Securities

Prior to the Withdrawal Date, at every meeting of the equity or interest holders of the Issuer called with respect to any matter, and at every adjournment or postponement thereof, and on every action or approval by written consent or resolution of the equity or interest holders of the Issuer, Investor agrees that the Record Owner shall vote Investor's Shares, in the event Investor's Shares contain voting rights, in a manner reasonably determined to be in the best interest of Investor.

### 3.4. Insurance

The Record Owner and Investor understand and agree that the Record Owner may maintain insurance in support of the Record Owner's obligations under this Agreement, including covering any loss of the Shares. In the event that the Record Owner elects to reduce, cancel or not to renew such insurance, the Record Owner may give Investor prior written notice as follows: in the case of a reduction, the Record Owner may endeavor to provide such notice at least 30 days prior to the effective date of the reduction; and in the event of a cancellation or expiration of the insurance without renewal, the Record Owner may provide such notice at least 30 days prior to the last day of insurance coverage. Investor acknowledges that any such insurance is held for the Record Owner's benefit and not for the benefit of Investor, and that Investor may not submit any claim under the terms of such insurance.

### 3.5. Notice of Changes

The Record Owner may notify Investor promptly in writing of the following: (i) the Record Owner receives notice of any claim against the Account other than a claim for payment of safe custody or administration permitted by this Agreement; (ii) the Record Owner otherwise fails to comply with any of the provisions of this Agreement; or (iii) any of the Record Owner's representations and warranties in clause 4 shall cease to be true and correct.

## 4. Obligations of the Portal

NetCapital shall notify or cause to be notified each Issuer of Shares of the identity of the Record Owner of the Shares of such Issuer.

## 5. Representations and Warranties

### 5.1 Investor's representations

Investor represents and warrants that:

- Investor is the beneficial owner of the Shares;
- Investor has all necessary authority, powers, consents, licenses and authorizations and has taken all necessary action to enable Investor lawfully to enter into and perform Investor's duties and obligations under this Agreement; and
- This Agreement and the obligations created under it are binding upon Investor and enforceable against Investor in accordance with its terms (subject to applicable principles of equity) and do not and will not violate the terms of the

rules or any order, charge or agreement by which Investor is bound.

## 5.2 The Record Owner's representations and warranties

The Record Owner represents and warrants to Investor that:

- this Agreement has been duly authorized, executed and delivered on the Record Owner's behalf and constitutes the Record Owner's legal, valid and binding obligation; and
- the execution, delivery and performance of this Agreement by the Record Owner does not and will not violate any agreement by which the Record Owner is bound.

## 6. Fees and Expenses

### 6.1 Fees

The Record Owner's fees will be paid in accordance with the fee agreement that has been executed by the Portal and the Record Owner. There are no fees payable by the Investor.

## 7. Scope of Responsibility

### 7.1 Exclusion of liability

The Record Owner may use reasonable care in the performance of its duties under this Agreement and will only be responsible for any loss or damage suffered by Investor as a direct result of any gross negligence, fraud or willful misconduct on the Record Owner's part in the performance of the Record Owner's duties, and in which case the Record Owner's liability will not exceed the aggregate market value of the Shares at the time of such gross negligence, fraud or willful misconduct.

### 7.2 Force majeure

Neither the Record Owner nor any of the Record Owner's directors, employees, agents or affiliates shall incur any liability to Investor if, by reason of any provision of any present or future law or regulation of any governmental or regulatory authority or stock exchange, or by reason of any act of God or war or terrorism, pandemic or other circumstances beyond the Record Owner's control, the Record Owner is prevented or forbidden from, or would be subject to any civil or criminal penalty on account of, or are delayed in, doing or performing any act or thing which by the terms of this Agreement it is provided shall be done or performed and accordingly the Record Owner does not do that thing or does that thing at a later time than would otherwise be required.

### 7.3 Exculpation in respect of offering documents

The Record Owner and its officers, directors, employees, agents and sub-record owners, if any, shall not be responsible or liable in any manner for any recitals, statements, representations or warranties made by any person other than the Record Owner including, but not limited to, statements contained in any material relating to

the offering and sale of Shares.

## 8. Termination

### 8.1 Method

The Record Owner may terminate this Agreement by giving not less than 60 Business Days' prior written notice to Investor and the Portal, provided that the Record Owner may terminate this Agreement immediately on written notice in the event that any of the statements set out in clause 4.1(a)-(c) become untrue. Clauses 6, 7.2 and 9 shall survive termination of this Agreement.

Investor may terminate this Agreement by giving not less than 60 Business Days' prior written notice to the Record Owner and the Portal in the event that the Record Owner is found, in a final determination not subject to appeal, to have committed an act of gross negligence or willful misconduct in respect of its duties as Record Owner hereunder.

### 8.2 Existing rights

Termination shall not affect rights and obligations then outstanding under this Agreement, which shall continue to be governed by this Agreement until all obligations have been fully performed.

### 8.3 Website

Effective upon the Termination Date, Investor's use of the Website will automatically be terminated and Investor will be permitted no further access to the Website until Investor has purchased other Shares.

## 9. Notices and Recordkeeping

### 9.1 Form

A notice or other communication given to Investor under or in connection with this Agreement may be given using the contact information Investor provided to the Portal.

### 9.2 Method of transmission

Any notice or other communication required to be in writing may be delivered by email, receipt confirmed, to the Portal or the Record Owner at the following email addresses:

If to the Record Owner:

MG Teixeira Inc
mannyteixeria@gmail.com

If to the Portal:

Netcapital Funding Portal Inc

## 10. General

### 10.1 No advice

The Record Owner’s duties and obligations under this Agreement do not include providing Investor with investment advice. In asking the Record Owner to open and maintain the Account, Investor does so in reliance upon Investor’s own judgment and the Record Owner shall not owe to Investor any duty to exercise any judgment on Investor’s behalf as to the merits or suitability of any deposits into, or withdrawals from, an Account.

### 10.2 Assignment

This Agreement is for the benefit of and binding upon the parties and their respective heirs, successors and assigns. Investor may not assign, transfer or encumber, or purport to assign, transfer or encumber, Investor’s right, title or interest in relation to any Account or any right or obligation under this Agreement or any part of any of the foregoing unless the Record Owner otherwise agrees in writing.

### 10.3 Amendments

Any amendment to this Agreement must be agreed in writing and be signed by all parties hereto. Unless otherwise agreed, an amendment will not affect any legal rights or obligations that may already have arisen.

### 10.4 Partial invalidity

If any of the clauses (or part of a clause) of this Agreement becomes invalid or unenforceable in any way, the validity of the remaining clauses (or part of a clause) will not in any way be affected or impaired.

### 10.5 Entire agreement

This document represents the entire agreement of the parties, and supersedes any previous agreements and understandings among the parties relating to the subject matter of this Agreement.

### 10.6 Joint and several liability

Investor’s responsibilities under this Agreement are joint and several if applicable.

### 10.7 Counterparts

This Agreement may be executed in any number of counterparts each of which when

executed and delivered is an original, but all the counterparts together constitute the same agreement.

### 10.8 Governing Law and Jurisdiction

This Agreement is governed by and construed in accordance with the laws of the State of Delaware without regard to its conflicts of laws principles. The parties agree that the United States District Court for the Delaware shall have sole and exclusive jurisdiction to determine any issues arising under this Agreement, and all Parties to this Agreement agree to submit to personal jurisdiction in Wilmington, Delaware, for the purpose of resolving any issue arising under or related to this Agreement.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM C

### UNDER THE SECURITIES ACT OF 1933

### Issuer Information

**Name of Issuer:** Addiction Cure Therapeutic Sciences Inc

**Legal Status:** Corporation

**Jurisdiction of Incorporation/Organization:** FL

**Date of Organization:** 04-28-2020

**Physical Address:** 6574 North State Road 7, Coconut Creek, FL, 34786

**Issuer Website:** https://www.addictioncuretherapeuticsciences.com/

**Is there a Co-Issuer?:** No

**Intermediary Name:** NetCapital Funding Portal Inc.

**Intermediary CIK:** 0001669191

**Intermediary File Number:** 007-00035

**Intermediary CRD Number:** 283596

### Offering Information

**Compensation to Intermediary:** Up to 4.9% of amount raised for a successful offering and a listing fee of up to $5,000

**Financial Interest in Issuer:** None.

**Type of Security Offered:** Common Stock

**Number of Securities Offered:** 20000

**Price per Security:** $0.50

**Method for Determining Price:** The price of the Securities was determined solely by the management and bears no relation to traditional measures of valuation such as book value or price-to-earnings ratios. We expect that any future valuation will take the same approach.

**Target Offering Amount:** $10,000.00

**Oversubscription Accepted:** Yes

**Oversubscription Allocation Type:** First-come, first-served basis

**Maximum Offering Amount:** $1,070,000.00

**Deadline to Reach Target Amount:** 03-03-2023

### Annual Report Disclosure Requirements

**Current Number of Employees:** 0

**Total Assets (Most Recent Fiscal Year):** $1,013.00

**Total Assets (Prior Fiscal Year):** $0.00

**Cash & Cash Equivalents (Most Recent Fiscal Year):** $1,013.00

**Cash & Cash Equivalents (Prior Fiscal Year):** $0.00

**Accounts Receivable (Most Recent Fiscal Year):** $0.00

**Accounts Receivable (Prior Fiscal Year):** $0.00

**Short-Term Debt (Most Recent Fiscal Year):** $3,729.00

**Short-Term Debt (Prior Fiscal Year):** $150.00

**Long-Term Debt (Most Recent Fiscal Year):** $0.00

**Long-Term Debt (Prior Fiscal Year):** $0.00

**Revenues/Sales (Most Recent Fiscal Year):** $0.00

**Revenues/Sales (Prior Fiscal Year):** $0.00

**Cost of Goods Sold (Most Recent Fiscal Year):** $0.00

**Cost of Goods Sold (Prior Fiscal Year):** $0.00

**Taxes Paid (Most Recent Fiscal Year):** $0.00

**Taxes Paid (Prior Fiscal Year):** $0.00

**Net Income (Most Recent Fiscal Year):** $-2,716.00

**Net Income (Prior Fiscal Year):** $-10,002.00

**Jurisdictions Offered:**

ALABAMA, ALASKA, ARIZONA, ARKANSAS, CALIFORNIA, COLORADO, CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, FLORIDA, GEORGIA, HAWAII, IDAHO, ILLINOIS, INDIANA, IOWA, KANSAS, KENTUCKY, LOUISIANA, MAINE, MARYLAND, MASSACHUSETTS, MICHIGAN, MINNESOTA, MISSISSIPPI, MISSOURI, MONTANA, NEBRASKA, NEVADA, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEW YORK, NORTH CAROLINA, NORTH DAKOTA, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, RHODE ISLAND, SOUTH CAROLINA, SOUTH DAKOTA, TENNESSEE, TEXAS, UTAH, VERMONT, VIRGINIA, WASHINGTON, WEST VIRGINIA, WISCONSIN, WYOMING, B5, GU, 1V, PR, VI

### Signatures

**Issuer:** Addiction Cure Therapeutic Sciences Inc

**Signature:** Jack Levine

**Title:** Principal Executive Officer

---

**Signature:** Jack Levine

**Title:** Principal Executive Officer

**Date:** 01-04-2023

---

**Signature:** Jack Levine

**Title:** Principal Financial Officer

**Date:** 01-04-2023

---

**Signature:** Michael Lambert

**Title:** Principal Accounting Officer

**Date:** 01-04-2023

---

**Signature:** Jack Levine

**Title:** Board Member

**Date:** 01-04-2023

---

**Signature:** Michael Lambert

**Title:** Board Member

**Date:** 01-04-2023